

DAVID E. BROOK
JAMES M. SMITH
LEO R. REYNOLDS
PATRICIA GRANAHAN
JOHN L. DUPRE
DAVID J. BRODY
MARY LOU WAKIMURA
THOMAS O. HOOVER
ALICE O. CARROLL
N. SCOTT PIERCE

ANNE J. COLLINS
ROBERT T. CONWAY
STEVEN G. DAVIS
CAROL A. EGNER
DOREEN M. HOGLE
J. GRANT HOUSTON
RODNEY D. JOHNSON
HELEN LEE
ELIZABETH W. MATA
TIMOTHY J. MEAGHER
ANTHONY P. ONELLO, JR.
NINA L. PEARLMUTTER
SCOTT D. ROTHENBERGER
DEIRDRE E. SANDERS
JAY SHIM
RICHARD W. WAGNER
LISA M. WARREN
HELEN E. WENDLER
DARRELL L. WONG



TWO MILITIA DRIVE · LEXINGTON, MASSACHUSETTS 02173-4799
TELEPHONE: (617) 861-6240 · FACSIMILE: (617) 861-9540

3540-101

MUNROE H. HAMILTON
(1906-1984)

OF COUNSEL
RICHARD A. WISE
SUSAN G. L. GLOVSKY

JOHN W. MEDBURY
ADMINISTRATIVE DIRECTOR
BARBARA J. FORGUE
PATENT ADMINISTRATOR

PATENT AGENTS
CAROLYN S. ELMORE

PATENTS, TRADEMARKS,
50%
RIGHTS AND
INVENTION S. PTO
08851089



Date: May 5, 1997

EXPRESS MAIL LABEL NO. EM080924599US

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith for filing is a continuation-in-part application filed under 37 CFR 1.53(b)(1) and claims priority to Serial No. NA filed April 7, 1997 entitled A SPHINGOMONAS BIODESULFURIZATION CATALYST by Aldis Darzins and Gregory T. Mrachko, the contents of which are incorporated herein by reference in its entirety.

Inventors: Aldis Darzins and Gregory T. Mrachko

Title: A SPHINGOMONAS BIODESULFURIZATION CATALYST

Specification, Claims, Abstract of the Disclosure

24 sheets of formal/informal drawings. (Figs. 1A-1D, 2A-2C, 3A-3C, 4, 5, 6A-6G, 7, 8, 9, 10 and 11)

An assignment of the invention to _____

A verified statement to establish small entity status under 37 C.F.R. 1.9 and 37 C.F.R. 1.27.

Unexecuted Combined Declaration/Power of Attorney.

Other: _____

The filing fee has been calculated as shown below:

(Col. 1)	(Col. 2)
FOR	NO. FILED
BASIC FEE	*****
TOTAL CLAIMS	75 - 20 = * 35
INDEP CLAIMS	28 - 3 = * 25
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIM PRESENTED	

*If the difference in Col. 1 is less than zero, enter "0" in Col. 2

SMALL ENTITY

RATE	FEES
*****	\$ 385
X \$11=	\$
X \$40=	\$
+ \$130=	\$
Assignment Fee	\$
Total:	\$

OTHER THAN A
SMALL ENTITY

RATE	FEES
*****	\$ 770
X \$22=	\$ 770
X \$80=	\$2,000
+ \$260=	\$
Assignment Fee	\$
Total:	\$ 3,540.00

- Please charge my Deposit Account No. 08-0380 in the amount of \$ _____
- A check in the amount of \$ 3,540.00 to cover the filing fee is enclosed.
- Authorization is hereby granted to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 08-0380. Two duplicate copies of this letter are enclosed.
- Any additional filing fees required under 37 CFR 1.16.
- Any patent application processing fees under 37 CFR 1.17.
- Authorization is hereby granted to charge payment of the following fees during pendency of this application or credit any overpayment to Deposit Account No. 08-0380. Two duplicate copies of this letter are enclosed.
- Any patent application processing fees under 37 CFR 1.17.
- Any filing fees under 37 CFR 1.16 for presentation of extra claims.

Respectfully submitted,
HAMILTON, BROOK, SMITH & REYNOLDS

By


Carolyn S. Elmore
Registration No.: 37,567
Agent for Applicants
Telephone: (617) 861-6240

Dated: 5/5/97

APPATENT.LTR-REV. 04/21/97

-1-

Date: May 5, 1997
EXPRESS MAIL LABEL NO. EM080924599US

Inventors: Aldis Darzins and Gregory T. Mrachko
Attorney's Docket No.: EBC97-06A

A *SPHINGOMONAS* BIODESULFURIZATION CATALYST

RELATED APPLICATIONS

This is a continuation-in-part application filed under 37 CFR 1.53(b) (1) and claims priority to Serial No. _____
5 filed April 7, 1997, entitled A *SPHINGOMONAS* BIODESULFURIZATION CATALYST by Aldis Darzins and Gregory T. Mrachko, the contents of which are incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

10 The microbial desulfurization of fossil fuels has been an area of active investigation for over fifty years. The object of these investigations has been to develop biotechnology based methods for the pre-combustion removal of sulfur from fossil fuels, such as coal, crude oil and
15 petroleum distillates. The driving forces for the development of desulfurization methods are the increasing levels of sulfur in fossil fuel and the increasingly stringent regulation of sulfur emissions. Monticello *et al.*, "Practical Considerations in Biodesulfurization of

Petroleum," IGT's 3d Intl. Symp. on Gas, Oil, Coal and Env. Biotech., (Dec. 3-5, 1990) New Orleans, LA.

Many biocatalysts and processes have been developed to desulfurize fossil fuels, including those described in U.S. 5 Patent Nos. 5,356,801, 5,358,870, 5,358,813, 5,198,341, 5,132,219, 5,344,778, 5,104,801 and 5,002,888, incorporated herein by reference. Economic analyses indicate that one limitation in the commercialization of the technology is improving the reaction rates and specific activities of the 10 biocatalysts, such as the bacteria and enzymes that are involved in the desulfurization reactions. The reaction rates and specific activities (sulfur removed/hour/gram of biocatalyst) that have been reported in the literature are much lower than those necessary for optimal commercial 15 technology. Therefore, improvements in the longevity and specific activity of the biocatalyst are desirable.

SUMMARY OF THE INVENTION

The invention relates to a novel microorganism, designated *Sphingomonas* sp. strain AD109, as well as 20 isolated proteins and nucleic acid sequences obtained from this microorganism. This microorganism was obtained using a soil enrichment process using 2-(2-hydroxyphenyl)benzenesulfinate as the sole sulfur source. A biologically pure sample of this microorganism has been 25 isolated and characterized.

The invention also relates to a collection of desulfurization enzymes isolated from *Sphingomonas* sp. strain AD109 which, together, catalyze the oxidative desulfurization of dibenzothiophene (DBT).

30 In another embodiment, the invention includes an isolated nucleic acid molecule, such as a DNA or RNA nucleotide sequence or molecule, which encodes one or more of the *Sphingomonas* desulfurization enzymes, or a homologue

or active fragment thereof. The invention also includes a recombinant microorganism containing one or more heterologous nucleic acid molecules which encode one or more of the *Sphingomonas* desulfurization enzymes or 5 homologues or active fragments thereof.

In a further embodiment, the invention provides a method of using the *Sphingomonas* microorganism or an enzyme preparation derived therefrom as a biocatalyst in the biocatalytic desulfurization of a fossil fuel containing 10 organosulfur compounds. The method comprises the steps of (1) contacting the fossil fuel with an aqueous phase containing a *Sphingomonas* biocatalyst which is capable of biocatalytic desulfurization and, optionally, a flavoprotein, thereby forming a fossil fuel and aqueous 15 phase mixture; (2) maintaining the mixture under conditions sufficient for sulfur oxidation and/or cleavage of the carbon-sulfur bonds of the organosulfur molecules by the biocatalyst, and (3) separating the fossil fuel having a reduced organic sulfur content from the resulting aqueous 20 phase.

The invention also provides a method of oxidizing an organic compound. The method comprises the steps of: (1) contacting the organic compound with an aqueous phase containing a *Sphingomonas* biocatalyst comprising at least 25 one enzyme capable of catalyzing at least one step in the oxidative cleavage of carbon-sulfur bonds, thereby forming an organic compound and aqueous phase mixture; (2) maintaining the mixture of step (1) under conditions sufficient for oxidation of the organic compound by the 30 biocatalyst, thereby resulting in an oxidized organic compound, and, optionally, separating the oxidized organic compound from the aqueous phase.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A, 1B, 1C and 1D together set forth the DNA sequence and the corresponding amino acid sequence of open reading frame 1 (ORF-1, *dszA*) of the nucleotide sequence required for desulfurization activity in *Sphingomonas* sp. strain AD109.

Figures 2A, 2B and 2C together set forth the DNA sequence and the corresponding amino acid sequence of open reading frame 2 (ORF-2, *dszB*) of the nucleotide sequence required for desulfurization activity in *Sphingomonas* sp. strain AD109.

Figures 3A, 3B and 3C together set forth the DNA sequence and the corresponding amino acid sequence of open reading frame 3 (ORF-3, *dszC*) of the nucleotide sequence required for desulfurization activity in *Sphingomonas* sp. strain AD109.

Figure 4 is a graph showing the disappearance of 2-(2-phenyl)benzenesulfinate (HPBS) and the appearance of 2-hydroxybiphenyl (2-HBP) in the presence of *Sphingomonas* AD109 cell-free lysates.

Figure 5 shows a physical map of the *Sphingomonas dsz* gene cluster.

Figures 6A, 6B, 6C, 6D, 6E, 6F and 6G together set forth the nucleotide sequence of the *Sphingomonas dsz* gene cluster.

Figure 7 is a physical map of the plasmid pDA296.

Figure 8 presents the results of a GAP analysis of the DszA proteins from *Sphingomonas* sp. strain AD109 and *Rhodococcus* IGTS8.

Figure 9 presents the results of a GAP analysis of the DszB proteins from *Sphingomonas* sp. strain AD109 and *Rhodococcus* IGTS8.

Figure 10 presents the results of a GAP analysis of the sequences of the DszC proteins from *Sphingomonas* sp. strain AD109 and *Rhodococcus* IGTS8.

Figure 11 is a physical map of the plasmid pEBCtac.

5 DETAILED DESCRIPTION OF THE INVENTION

The present invention is based on the discovery and isolation of a novel microorganism which is capable of selectively desulfurizing dibenzothiophene ("DBT"). As described in Example 1, this microorganism was obtained 10 from soil samples obtained at sites contaminated with petroleum and petroleum by-products by a soil enrichment procedure using 2-(2-hydroxyphenyl)benzenesulfinate as the sole sulfur source. A biologically pure sample of the novel microorganism has been isolated and characterized. 15 The microorganism is a motile, gram-negative rod. Based on a fatty acid analysis, as described in Example 2, this microorganism has been identified as a *Sphingomonas* species, and designated strain AD-109. This microorganism has been deposited at the American Type Culture Collection 20 (ATCC), 12301 Park Lawn Drive, Rockville, Maryland, U.S.A. 20852 under the terms of the Budapest Treaty and has been designated as ATCC Deposit No. 55954 on April 21, 1997.

The novel microorganism of the invention can be grown by fermentation under aerobic conditions in the presence of 25 a sulfur-free mineral salts medium (e.g., 4 g/L K₂HPO₄, 4 g/L Na₂HPO₄, 2 g/L NH₄Cl, 0.2 g/L MgCl₂.6H₂O, 0.001 g/L CaCl₂.2H₂O, and 0.001 g/L FeCl₃.6H₂O), containing a sulfur-free source of assimilable carbon such as glucose. The sole source of sulfur provided can be a heterocyclic 30 organosulfur compound, such as dibenzothiophene or a derivative thereof.

Sphingomonas sp. strain AD109 expresses a collection of enzymes which together catalyze the conversion of DBT to

2-hydroxybiphenyl (also referred to as "2-HBP") and inorganic sulfur. An enzyme which catalyzes one or more steps in this overall process is referred to herein as a "desulfurization enzyme". The nucleic acid sequence required for this overall process has been identified and cloned using the general method described in U.S. Patent No. 5,356,801, the contents of which are incorporated herein by reference, and is set forth in Figure 6 (SEQ ID NO.: 12). This nucleic acid sequence (also referred to as the "*Sphingomonas dsz* sequence") comprises three open reading frames, designated ORF-1 (base pairs 442-1800, also set forth in Figures 1A-1D and SEQ ID NO.: 1), ORF-2 (base pairs 1800-2909, also set forth in Figures 2A-2C and SEQ ID NO.: 3) and ORF-3 (base pairs 2906-4141, sequence also set forth in Figures 3A-3C and SEQ ID NO.: 5). The predicted amino acid sequences encoded by these open reading frames are set forth in Figures 1A-1D (ORF-1, SEQ ID NO: 2), Figures 2A-2C (ORF-2, SEQ ID NO.: 4) and Figures 3A-3C (ORF-3, SEQ ID NO.: 6). Each of these open reading frames is homologous to the corresponding open reading frame of *Rhodococcus* sp. IGTS8; the sequences of the *Rhodococcus* open reading frames are disclosed in U.S. Patent No. 5,356,801.

In one embodiment, the present invention provides an isolated nucleic acid molecule comprising one or more nucleotide sequences which encode one or more of the biodesulfurization enzymes of *Sphingomonas* sp. strain AD109. The isolated nucleic acid molecule can be, for example, a nucleotide sequence, such as a deoxyribonucleic acid (DNA) sequence or a ribonucleic acid (RNA) sequence. Such a nucleic acid molecule comprises one or more nucleotide sequences which encode one or more of the amino acid sequences set forth in SEQ ID NO.: 2, SEQ ID NO.: 4, and SEQ ID NO.: 6. For example, the isolated nucleic acid

- molecule can comprise one or more of the nucleotide sequences of SEQ ID NO.: 1, SEQ ID NO.: 3, and SEQ ID NO.: 5, or a complement of any of these sequences. The isolated nucleic acid molecule can also comprise a nucleotide sequence which results from a silent mutation of one or more of the sequences set forth in SEQ ID NO.: 1, SEQ ID NO.: 3, and SEQ ID NO.: 5. Such a nucleotide sequence can result, for example, from a mutation of the native sequence in which one or more codons have been replaced with a degenerate codon, i.e., a codon which encodes the same amino acid. Such mutant nucleotide sequences can be constructed using methods which are well known in the art, for example the methods discussed by Ausubel *et al.*, *Current Protocols in Molecular Biology*, Wiley-Interscience, New York (1997) (hereinafter "Ausubel *et al.*") and by Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, third edition, Cold Spring Harbor Laboratory Press (1992) (hereinafter "Sambrook *et al.*"), each of which are incorporated herein by reference.
- In another embodiment, the invention includes an isolated nucleic acid molecule comprising a nucleotide sequence which is homologous to one or more of the sequences of SEQ ID NO.: 1, SEQ ID NO.: 3, and SEQ ID NO.: 5, or complements thereof. Such a nucleotide sequence exhibits at least about 80% homology, or sequence identity, with one of these *Sphingomonas* nucleotide sequences, preferably at least about 90% homology or sequence identity. Particularly preferred sequences have at least about 95% homology or have essentially the same sequence.
- Preparation of mutant nucleotide sequences can be accomplished by methods known in the art as are described in Old, *et al.*, *Principles of Gene Manipulation*, Fourth

Edition, Blackwell Scientific Publications (1989), in Sambrook et al., and in Ausubel et al.

The invention further includes nucleic acid molecules which are useful as hybridization probes, for example, for

5 the isolation of the *Sphingomonas* genes encoding desulfurization enzymes or identical or homologous genes from other organisms. Such molecules comprise nucleotide sequences which hybridize to all or a portion of the nucleotide sequence of SEQ ID NO.: 1, SEQ ID NO.: 3 or SEQ

10 ID NO.: 5 or to non-coding regions immediately (within about 1000 nucleotides) 5' or 3' of each open reading frame. The invention also includes an isolated nucleic acid molecule which comprises a fragment of one or more of the nucleotide sequences set forth in SEQ ID NO.: 1, SEQ ID

15 NO.: 3 or SEQ ID NO.: 5 or complements of any of these sequences. Such a fragment will generally comprise at least about 20 or at least about 40 contiguous nucleotides and, preferably, at least about 50 contiguous nucleotides of one of the disclosed sequences. Preferably, the

20 hybridization probe of the invention hybridizes to one of these sequences under stringent conditions, such as those set forth by Sambrook et al. and Ausubel et al. For example, under conditions of high stringency, such as high temperatures and low salt concentrations, only DNA

25 molecules which are essentially exact matches, or complements, will hybridize, particularly if the probe is relatively short. Hybridization under conditions of lower stringency, such as low temperatures, low formamide concentrations and high salt concentrations, allows greater

30 mismatch between the probe and the target DNA molecule. It is particularly preferred that the nucleic acid molecule hybridizes selectively to the disclosed sequence(s).

The nucleic acid molecules can be synthesized chemically from the disclosed sequences. Alternatively,

the nucleic acid molecules can be isolated from a suitable nucleic acid library (such as a DNA library) obtained from a microorganism which is believed to possess the nucleic acid molecule (such as, *Sphingomonas* sp. strain AD109),

- 5 employing hybridizing primers and/or probes designed from the disclosed sequences. Such a method can result in isolating the disclosed molecules (or spontaneous mutants thereof) for use in preparing recombinant enzymes, confirming the disclosed sequences, or for use in
- 10 mutagenizing the native sequences.

In yet another embodiment, the nucleic acid molecule of the present invention can be a nucleic acid molecule, such as a recombinant DNA molecule, resulting from the insertion into its chain by chemical or biological means, of one or more of the nucleotide sequences described above. Recombinant DNA includes any DNA synthesized by procedures using restriction nucleases, nucleic acid hybridization, DNA cloning, DNA synthesis or any combination of the preceding. Methods of construction can be found in

- 15 Sambrook et al. and Ausubel et al., and additional methods are known by those skilled in the art.
- 20

The isolated nucleic acid molecule of the invention can further comprise a nucleotide sequence which encodes an oxidoreductase, such as a flavoprotein, such as a flavin reductase. For example, the nucleic acid molecule can encode an oxidoreductase which is native to *Sphingomonas* sp. strain AD109. The nucleic acid molecule can also encode the oxidoreductase denoted DszD described in copending U.S. Patent Application Serial No. 08/583,118; the flavin reductase from *Vibrio harveyii* described in copending U.S. Patent Application Serial No. 08/351,754; or the flavin reductase from *Rhodococcus* sp. IGTS8, described in copending U.S. Patent Application Serial No. 08/735,963.

The contents of each of these applications are incorporated herein by reference.

The invention also includes a plasmid or vector comprising a recombinant DNA sequence or molecule which

5 comprises one or more of the nucleic acid molecules, e.g. nucleotide sequences, of the invention, as described above. The terms "plasmid" and "vector" are intended to encompass any replication competent or replication incompetent plasmid or vector capable of having foreign or exogenous

10 DNA inserted into it by chemical or biological means and subsequently, when transformed into an appropriate non-human host organism, of expressing the product of the foreign or exogenous DNA insert (e.g., of expressing the biocatalyst and flavoprotein of the present invention). In

15 addition, the plasmid or vector is receptive to the insertion of a DNA molecule or fragment thereof containing the gene or genes of the present invention, said gene or genes encoding a biocatalyst as described herein.

Procedures for the construction of DNA plasmid vectors

20 include those described in Sambrook et al. and Ausubel et al. and others known by those skilled in the art.

The plasmids of the present invention include any DNA fragment containing a nucleotide sequence as described above. The DNA fragment should be transmittable, for

25 example, to a host microorganism by transformation or conjugation. Procedures for the construction or extraction of DNA plasmids include those described in Sambrook et al. and Ausubel et al., and others known by those skilled in the art. In one embodiment, the plasmid comprises a

30 nucleotide sequence of the invention operatively linked to a competent or functional regulatory sequence. Examples of suitable regulatory sequences include promoters, enhancers, transcription binding sites, ribosomal binding sites, transcription termination sequences, etc.

In one preferred embodiment, the regulatory or promoter sequences are those native to the *Sphingomonas* operon containing the genes disclosed herein. In yet another embodiment, one or more regulatory sequences (e.g. 5 the promoter) is native to the selected host cell for expression. The promoter can be selected so that the gene or genes are inducible or constitutively expressed. Furthermore, the sequences can be regulated individually or together, as an operon. Examples of suitable promoters 10 include the *E. coli lac* and *tac* promoters and the *Pseudomonas P_G* promoter (Yen, *J. Bacteriol.* 173 : 5328-5335 (1991)). An example of such a plasmid and its construction are described in Example 8.

In another embodiment, the invention relates to a 15 recombinant or transformed non-human host organism which contains a heterologous DNA molecule of the invention as described above. The recombinant non-human host organisms of the present invention can be created by various methods by those skilled in the art. Any method for introducing a 20 recombinant plasmid, such as a plasmid of the invention described above, into the organism of choice can be used, and a variety of such methods are described by Sambrook et al. and Ausubel et al. For example, the recombinant plasmid can be introduced via a suitable vector by 25 transformation, conjugation, transduction or electroporation. By the term "non-human host organism" is intended any non-human organism capable of the uptake and expression of foreign, exogenous or recombinant DNA.

The recombinant microorganism can be derived from a 30 host organism which does not express a native desulfurization biocatalyst. Such microorganisms include bacteria and yeasts, e.g., *E. coli*, *Bacillus*, and non-desulfurizing pseudomonads (as described in U. S. Patent

Application Serial Number _____ (Attorney Docket No. EBC96-06A, being filed concurrently herewith)). In another embodiment, the recombinant microorganism is derived from a host organism which expresses a native biodesulfurization catalyst. Preferred microorganisms of this type are *Rhodococcus* sp. IGTS8 (ATCC 53968), recombinant microorganisms comprising one or more of the IGTS8 desulfurizing genes and *Sphingomonas* sp. strain AD109. Other desulfurizing microorganisms which are suitable host organisms include *Corynebacterium* sp. strain SY1, as disclosed by Omori et al., *Appl. Env. Microbiol.*, **58** : 911-915 (1992); *Rhodococcus erythropolis* D-1, as disclosed by Izumi et al., *Appl. Env. Microbiol.*, **60** :223-226 (1994); the *Arthrobacter* strain described by Lee et al., *Appl. Environ. Microbiol.* **61** : 4362-4366 (1995); the *Agrobacterium* strain disclosed by Constanti et al., *Enzyme Microb. Tech.* **19** : 214-219 (1996) and the *Rhodococcus* strains (ATCC 55309 and ATCC 55310) disclosed by Grossman et al., U.S. Patent No. 5,607,857, each of which is incorporated herein by reference in its entirety. Each of these microorganisms produces one or more enzymes (protein biocatalysts) that catalyze one or more reactions in the desulfurization of DBT.

The invention also relates to desulfurization enzymes which can be isolated from *Sphingomonas* sp. strain AD109. These include desulfurization enzymes which catalyze one or more steps in the oxidative desulfurization of DBT. The enzyme encoded by ORF-2 has been partially purified and exhibits 2-(2-hydroxyphenyl)benzenesulfinate (HPBS) desulfinase activity and has an apparent molecular weight by denaturing gel electrophoresis of about 40,000 daltons.

In one embodiment, the invention includes an isolated desulfurization enzyme from *Sphingomonas* sp. strain AD109 using methods and assays which are known the art, for example, the methods used by Gray et al. to isolate and 5 characterize desulfurization enzymes from *Rhodococcus* IGTS8 (Gray et al., *Nature Biotech.* 14 : 1705-1709 (1996)). These enzymes can be isolated or purified from the cell by lysing the cell and subjecting the cell lysate to known protein purification methods, and testing the fractions 10 obtained thereby for the desired enzymatic activity. Examples of suitable protein purification methods include ammonium sulfate precipitation, ultrafiltration, diafiltration, immunoabsorption, anion exchange chromatography, gel filtration chromatography and 15 hydrophobic interaction chromatography. The enzymes of the invention can also be recombinant proteins produced by heterologous expression of a nucleic acid molecule comprising a nucleotide sequence of SEQ ID NO.: 1, SEQ ID NO.: 3 or SEQ ID NO.: 5; or a mutation or fragment thereof, 20 as discussed above. When the recombinant organism is derived from a non-*Sphingomonas* host, the recombinant proteins can be prepared in a form which is substantially free of other *Sphingomonas* proteins.

The invention also includes an isolated enzyme having 25 an amino acid sequence which is homologous to the amino acid sequence of SEQ ID NO.: 2, SEQ ID NO.: 4 or SEQ ID NO.: 6, or fragments thereof. The term "homologous" or "homologue", as used herein, describes a protein (which is not obtained from *Rhodococcus* or *Rhodococcus* sp IGTS8) 30 having at least about 80% sequence identity or homology with the reference protein, and preferably about 90% sequence homology, in an amino acid alignment. Most preferably, the protein exhibits at least about 95%

homology or essentially the same sequence as the disclosed sequence. An amino acid alignment of two or more proteins can be produced by methods known in the art, for example, using a suitable computer program, such as BLAST (Altschul et al., J. Mol. Biol. 215 : 403-410 (1990)). A homologous protein can also have one or more additional amino acids appended at the carboxyl terminus or amino terminus, such as a fusion protein.

The homologous enzymes described herein can be native to an organism, such as a desulfurizing microorganism, including *Sphingomonas* sp. strain AD109 and mutants thereof. Such enzymes can be isolated from such sources using standard techniques and assays, as are described in the Exemplification and others known in the art. For example, the *Sphingomonas* desulfurization enzymes can be used to induce the formation of antibodies, such as monoclonal antibodies, according to known methods. The antibodies can then be used to purify the desulfurization enzymes from a desulfurizing organism via affinity chromatography, as is well known in the art.

The homologous enzymes of the invention can also be non-naturally occurring. For example, a homologous enzyme can be a mutant desulfurization enzyme which has a modified amino acid sequence resulting from the deletion, insertion or substitution of one or more amino acid residues in the amino acid sequence of a *Sphingomonas* desulfurization enzyme. Such amino acid sequence variants can be prepared by methods known in the art. For example, the desired polypeptide can be synthesized *in vitro* using known methods of peptide synthesis. The amino acid sequence variants are preferably made by introducing appropriate nucleotide changes into a DNA molecule encoding the native enzyme, followed by expression of the mutant enzyme in an

appropriate vector, such as *E. coli*. These methods include site-directed mutagenesis or random mutagenesis, for example.

Particularly preferred mutants include those having 5 amino acid sequences which include the amino acid residues which are encoded by both SEQ ID NO.: 1, SEQ ID NO.: 3 or SEQ ID NO.: 5 and the corresponding open reading frame of *Rhodococcus* sp. IGTS8, as disclosed in U.S. Patent No. 5,356,801. That is, these mutants include the amino acid 10 residues which are conserved in these two organisms in an amino acid alignment. Mutants which result from conservative substitution of one or more of these conserved residues, as well as non-conserved residues, are also included. Conservative and non-conservative substitutions 15 (including deletions and insertions) can be made in non-conserved regions of the amino acid sequence and mutants resulting from both conservative and non-conservative substitutions of these residues are included herein.

Conservative substitutions are those in which a first 20 amino acid residue is substituted by a second residue having similar side chain properties. An example of such a conservative substitution is replacement of one hydrophobic residue, such as valine, with another hydrophobic residue, such as leucine. A non-conservative substitution involves 25 replacing a first residue with a second residue having different side chain properties. An example of this type of substitution is the replacement of a hydrophobic residue, such as valine, with an acidic residue, such as glutamic acid.

30 The two primary variables in the construction of amino acid sequence variants are (1) the location of the mutation site and (2) the nature of the mutation. These variables can be manipulated to identify amino acid residues at the active site of the enzyme. For example, an amino acid

substitution which yields a mutant enzyme having significantly different activity than the native enzyme suggests that the substituted amino acid residue is at the active site. Such mutants can have the same or similar, 5 increased or decreased activity relative to that of the native enzyme.

Amino acids can be modified, for example, by substituting first with a conservative choice, followed by non-conservative choices depending upon the results 10 achieved, by deleting the target residue(s) or by inserting residues adjacent to a particular site. Variants can also be constructed using a combination of these approaches.

The proteins of the present invention can be produced using techniques to overexpress the gene, as are described 15 by Sambrook et al. and Ausubel et al. Improved expression, activity or overexpression of the *Sphingomonas* desulfurization enzymes (in *Sphingomonas* sp AD 109 or in recombinant host cells harboring the disclosed nucleic acid molecules) can also be accomplished by mutagenesis. 20 Suitable mutagens include radiation, e.g., ultraviolet radiation, and chemical mutagens, such as N-methyl-N'-nitroso-guanidine, hydroxylamine, ethylmethanesulfonate and nitrous acid. Furthermore, spontaneous mutants can be selected where the microorganism is subjected to an 25 enrichment culture, as exemplified herein. The mutagenesis and subsequent screening for mutants harboring increased enzymatic activity can be conducted according to methods generally known in the art.

The present invention also provides a method of 30 desulfurizing a carbonaceous material containing organosulfur molecules. The carbonaceous material can be, for example, a DBT-containing material or a fossil fuel, such as petroleum, a petroleum distillate fraction or coal. The method comprises the steps of (1) contacting the

carbonaceous material with an aqueous phase containing a *Sphingomonas*-derived biocatalyst comprising at least one enzyme capable of catalyzing at least one step in the oxidative cleavage of carbon-sulfur bonds, thereby forming
5 a carbonaceous material and aqueous phase mixture; (2) maintaining the mixture of step (1) under conditions sufficient for biocatalysis; and (3) separating the carbonaceous material having a reduced organic sulfur content from the resulting aqueous phase.

10 The term "*Sphingomonas*-derived biocatalyst", as used herein, is a biocatalyst which includes one or more desulfurization enzymes encoded by SEQ ID NO.: 1, SEQ ID NO.: 3 and SEQ ID NO.: 5; or a mutant or homologue thereof.

15 In one embodiment, the biocatalyst is a microorganism, such as *Sphingomonas* sp. strain AD109. The biocatalyst can also be a recombinant organism which contains one or more heterologous nucleotide sequences or nucleic acid molecules as described above.

20 Although living microorganisms (e.g., a culture) can be used as the biocatalyst herein, this is not required. Biocatalytic enzyme preparations that are useful in the present invention include microbial lysates, extracts, fractions, subfractions, or purified products obtained by conventional means and capable of carrying out the desired
25 biocatalytic function. Generally, such enzyme preparations are substantially free of intact microbial cells. In a particularly preferred embodiment, the biocatalyst is overexpressed in the recombinant host cell (such as a cell which contains more than one copy of the gene or genes).

30 Enzyme biocatalyst preparations suitable for use herein can optionally be affixed to a solid support, e.g., a membrane, filter, polymeric resin, glass particles or beads, or ceramic particles or beads. The use of immobilized enzyme preparations facilitates the separation

of the biocatalyst from the treated fossil fuel which has been depleted of refractory organosulfur compounds.

A fossil fuel that is suitable for desulfurization treatment according to the present invention is one that 5 contains organic sulfur. Such a fossil fuel is referred to as a "substrate fossil fuel". Substrate fossil fuels that are rich in thiophenic sulfur are particularly suitable for desulfurization according to the method described herein. Examples of such substrate fossil fuels include Cerro Negro 10 or Orinoco heavy crude oils; Athabascan tar and other types of bitumen; petroleum refining fractions such as gasoline, kerosene, diesel, fuel oil, residual oils and miscellaneous refinery by-products; shale oil and shale oil fractions; and coal-derived liquids manufactured from sources such as 15 Pocahontas #3, Lewis-Stock, Australian Glencoe or Wyodak coal.

In the petroleum extraction and refining arts, the term "organic sulfur" is generally understood as referring to organic molecules having a hydrocarbon framework to 20 which one or more sulfur atoms are covalently joined.

These sulfur atoms can be directly bonded to the hydrocarbon framework, e.g., by one or more carbon-sulfur bonds, or can be present in a substituent bonded to the hydrocarbon framework of the molecule, e.g., a sulfate 25 group. The general class of organic molecules having one or more sulfur heteroatoms are sometimes referred to as "organosulfur compounds". The hydrocarbon portion of these compounds can be aliphatic and/or aromatic.

Sulfur-bearing heterocycles, such as substituted and 30 unsubstituted thiophene, benzothiophene, and dibenzothiophene, are known to be stable to conventional desulfurization treatments, such as hydrodesulfurization (HDS). Sulfur-bearing heterocycles can have relatively simple or relatively complex chemical structures. In 35 complex heterocycles, multiple condensed aromatic rings,

one or more of which can be heterocyclic, are present. The difficulty of desulfurization generally increases with the structural complexity of the molecule. That is, refractory behavior is particularly accentuated in complex sulfur-bearing heterocycles, such as dibenzothiophene (DBT, C₁₂H₈S).

Much of the residual post-HDS organic sulfur in fossil fuel refining intermediates and combustible products is thiophenic sulfur. The majority of this residual thiophenic sulfur is present in DBT and derivatives thereof having one or more alkyl or aryl groups attached to one or more carbon atoms present in one or both flanking benzo rings. DBT itself is accepted as a model compound illustrative of the behavior of the class of compounds encompassing DBT and derivatives thereof in reactions involving thiophenic sulfur (Monticello and Finnerty, *Ann. Rev. Microbiol.*, 39 : 371-389 (1985)). DBT and derivatives thereof can account for a significant percentage of the total sulfur content of particular crude oils, coals and bitumen. For example, these sulfur-bearing heterocycles have been reported to account for as much as 70 wt% of the total sulfur content of West Texas crude oil, and up to 40 wt% of the total sulfur content of some Middle East crude oils. Thus, DBT is considered to be particularly relevant as a model compound for the forms of thiophenic sulfur found in fossil fuels, such as crude oils, coals or bitumen of particular geographic origin, and various refining intermediates and fuel products manufactured therefrom (Monticello and Finnerty (1985), *supra*). Another characteristic of DBT and derivatives thereof is that, following a release of fossil fuel into the environment, these sulfur-bearing heterocycles persist for long periods of time without significant biodegradation. Gundlach et al., *Science* 221 : 122-129 (1983). Thus, most prevalent naturally

occurring microorganisms do not effectively metabolize and break down sulfur-bearing heterocycles.

Biocatalytic desulfurization (biocatalysis or BDS) is the excision (liberation or removal) of sulfur from organosulfur compounds, including refractory organosulfur compounds such as sulfur-bearing heterocycles, as a result of the oxidative, preferably selective, cleavage of carbon-sulfur bonds in said compounds by a biocatalyst. BDS treatment yields the desulfurized combustible hydrocarbon framework of the former refractory organosulfur compound, along with inorganic sulfur substances which can be readily separated from each other by known techniques such as fractional distillation or water extraction. For example, DBT is converted into 2-hydroxybiphenyl when subjected to BDS treatment. A suitable biocatalyst for BDS comprises *Sphingomonas* sp. strain AD109 or an enzyme preparation derived therefrom, optionally, in combination with one or more additional non-human desulfurizing organisms (e.g., microorganisms); or an enzyme preparation derived from such an organism. Suitable additional desulfurizing organisms include those described above.

The specific activity of a given biocatalyst is a measure of its biocatalytic activity per unit mass. Thus, the specific activity of a particular biocatalyst depends on the nature or identity of the microorganism used or used as a source of biocatalytic enzymes, as well as the procedures used for preparing and/or storing the biocatalyst preparation. The concentration of a particular biocatalyst can be adjusted as desired for use in particular circumstances. For example, where a culture of living microorganisms, such as *Sphingomonas* sp. strain AD109, is used as the biocatalyst preparation, a suitable culture medium lacking a sulfur source other than sulfur-bearing heterocycles can be inoculated with suitable microorganisms

and grown until a desired culture density is reached. The resulting culture can be diluted with additional medium or another suitable buffer, or microbial cells present in the culture can be retrieved e.g., by centrifugation, and
5 resuspended at a greater concentration than that of the original culture. The concentrations of microorganism and enzyme biocatalyst can be adjusted similarly. In this manner, appropriate volumes of biocatalyst preparations having predetermined specific activities and/or concentra-
10 tions can be obtained.

In the biocatalytic desulfurization stage, the liquid fossil fuel containing sulfur-bearing heterocycles is combined with the biocatalyst. The relative amounts of biocatalyst and liquid fossil fuel can be adjusted to suit
15 particular conditions, or to produce a particular level of residual sulfur in the treated, deeply desulfurized fossil fuel. The amount of biocatalyst preparation to be combined with a given quantity of liquid fossil fuel will reflect the nature, concentration and specific activity of the
20 particular biocatalyst used, as well as the nature and relative abundance of inorganic and organic sulfur compounds present in the substrate fossil fuel and the degree of deep desulfurization sought or considered acceptable.

The method of desulfurizing a fossil fuel of the present invention involves two aspects. First, a host organism or biocatalytic preparation obtained therefrom is contacted with a fossil fuel to be desulfurized. This can be done in any appropriate container, optionally fitted
30 with an agitation or mixing device. The mixture is combined thoroughly and maintained or allowed to incubate for a sufficient time to allow for biocatalysis. In one embodiment, an aqueous emulsion or microemulsion is produced with an aqueous culture of the organism or enzyme fraction and the fossil fuel, allowing the organism to

propagate in the emulsion while the expressed biocatalyst cleaves carbon-sulfur bonds.

Variables such as temperature, pH, oxidation levels, mixing rate and rate of desulfurization will vary according
5 to the nature of the biocatalyst used. Optimal parameters can generally be determined through no more than routine experimentation.


When the fossil fuel is a liquid hydrocarbon, such as petroleum, the desulfurized fossil fuel and the aqueous
10 phase can form an emulsion. The components of such emulsions can be separated by a variety of methods, such as those described in U.S. Patent No. 5,358,870 and U.S. Patent Application Serial No. 08/640,129, which are incorporated herein by reference. For example, some
15 emulsions reverse spontaneously when maintained under stationary conditions for a suitable period of time. Other emulsions can be reversed by adding an additional amount of an aqueous phase. Still other emulsions can be separated by the addition of a suitable chemical agent, such as a
20 demulsifying agent or by employing suitable physical conditions, such as a particular temperature range.

The biocatalyst can be recovered from the aqueous phase, for example, by centrifugation, filtration or lyophilization. When the biocatalyst is a microorganism,
25 the biocatalyst can be resuspended in fresh sulfur-free nutrient medium and/or any fresh microorganism culture as necessary to reconstitute or replenish to the desired level of biocatalytic activity. The biocatalyst can then be reintroduced into the reaction system.

30 Several suitable techniques for monitoring the rate and extent of desulfurization are well-known and readily available to those skilled in the art. Baseline and time course samples can be collected from the incubation mixture, and prepared for a determination of the residual
35 organic sulfur in the fossil fuel. The disappearance of

- sulfur from organosulfur compounds, such as DBT, in the sample being subjected to biocatalytic treatment can be monitored using, e.g., X-ray fluorescence (XRF) or atomic emission spectrometry (flame spectrometry). Preferably,
5 the molecular components of the sample are first separated, e.g., by gas chromatography.

Without being limited to any particular mechanism or theory, it is believed that the pathway of the desulfurization reaction in *Sphingomonas* sp. strain AD109
10 and other desulfurizing organisms, such as *Rhodococcus* sp. IGTS8, is set forth below:



- Here the flavin reductase provides an electron transport chain which delivers, via FMNH₂, the reducing equivalents
15 from NADH (or other electron donor) to the enzymes DszC and/or DszA. The enzyme DszC is responsible for the biocatalysis of the oxidation reaction of DBT to DBTO₂. The enzyme DszA is responsible for the reaction of DBTO₂ to

2-(2-hydroxyphenyl)benzenesulfinate (HPBS). The enzyme DszB catalyzes the conversion of HPBS to 2-hydroxybiphenyl and inorganic sulfur.

- Another method of use of the *Sphingomonas*
- 5 desulfurization enzymes, or mutants, homologues or active fragments thereof, is as a biocatalyst for the oxidation of organic compounds, such as substituted or unsubstituted dibenzothiophenes. The method comprises the steps of (1) contacting the organic compound with an aqueous phase
- 10 containing a *Sphingomonas*-derived biocatalyst comprising at least one enzyme capable of catalyzing at least one step in the oxidative cleavage of carbon-sulfur bonds, thereby forming an organic compound and aqueous phase mixture; (2) maintaining the mixture of step (1) under conditions
- 15 sufficient for oxidation of the organic compound by the biocatalyst, thereby resulting in an oxidized organic compound, and, optionally, separating the oxidized organic compound from the aqueous phase. In one embodiment, the organic compound is a heteroorganic compound, such as an
- 20 organonitrogen compound or an organosulfur compound. In one embodiment, the organic compound is an organosulfur compound which is a component of a fossil fuel, such as petroleum or a petroleum distillate fraction. In a second embodiment, the organic compound is a substituted or
- 25 unsubstituted indole, as described in U.S. Provisional Patent Application Serial Number 60/020563, filed July 2, 1996, which is incorporated herein by reference.

The enzyme encoded by the nucleotide sequence of ORF-3 catalyzes the oxidation of dibenzothiophene to

30 dibenzothiophene-5,5-dioxide (dibenzothiophene sulfone), and the enzyme encoded by the nucleotide sequence of ORF-1 catalyzes the oxidation of dibenzothiophene-5,5-dioxide to 2-(2-hydroxyphenyl)benzenesulfinate (also referred to as "HPBS"). In one embodiment the biocatalyst comprises the

enzyme encoded by ORF-3, or a mutant, homologue or active fragment thereof; the organosulfur compound is substituted or unsubstituted dibenzothiophene; and the oxidized organosulfur is a substituted or unsubstituted

5 dibenzothiophene-5,5-dioxide or dibenzothiophene-5-oxide (dibenzothiophene sulfoxide). In another embodiment the biocatalyst comprises the enzymes encoded by ORF-1 and ORF-3, or a mutant, homologue or active fragment thereof; the organosulfur compound is a substituted or unsubstituted

10 dibenzothiophene; and the oxidized organosulfur compound is a substituted or unsubstituted 2-(2-hydroxyphenyl)benzenesulfinate. In yet another embodiment, the biocatalyst comprises the enzyme encoded by ORF-1 or a mutant, homologue or active fragment thereof; the

15 organosulfur compound is a substituted or unsubstituted dibenzothiophene-5,5-dioxide; and the oxidized organosulfur compound is a substituted or unsubstituted 2-(2-hydroxyphenyl)benzenesulfinate.

The oxidized organosulfur compound can, optionally, be further processed, for example, via a non-biological process or an enzyme-catalyzed reaction. In one embodiment, the oxidized organosulfur compound is desulfurized in a process employing suitable desulfurization enzymes from an organism other than a

25 *Sphingomonas*.

The biocatalyst can be an organism, such as *Sphingomonas* sp. strain AD109, a desulfurizing mutant thereof, or a recombinant organism or enzyme preparation, as discussed above. When the organosulfur compound is a component of a fossil fuel, suitable reaction conditions and fossil fuel sources can be determined as described above.

The invention will now be further illustrated by the way of the following examples.

EXAMPLES

General Methods and Materials

Bacterial strains and plasmids

E. coli DH10 β ($F^- mcrA$

5 $\Delta(mrr-hsdRMS-mcrBC)$ phi80dlacZ Δ M15 $\Delta lacX74$ *deoR recA1 endA1*
ara Δ 139 $\Delta(ara, leu)7697$ *galU galK lambda* $^+$ *rpsL nupG*;
Gibco-BRL, Gaithersburg, MD) was used as the cloning host.
Plasmids pUC18 (Ap^R ; Vieria and Messing, Gene 19 :
259-268, (1982)), pOK12 (Km^R ; Vieria and Messing, Gene 100
10 : 189-194 (1991)) and pSL1180 (Ap^R ; Brosius, DNA 8 : 759,
(1989)) were used as cloning vectors. Plasmid pEBCTac (Ap^R
 Tc^R *lacI* q *tac*, shown in Figure 11, was used to
overexpress the *Sphingomonas dszb* in *E. coli*.

Media and Reagents

15 Luria broth (LB) medium was routinely used to propagate *E. coli*. LB medium is 1% tryptone (Difco), 0.5% yeast extract (Difco) and 0.5% NaCl. Rich medium (RM) was used to propagate *Sphingomonas* strain AD109. RM medium is 0.8% nutrient broth, 0.05% yeast extract and 1% glucose.
20 2YT medium, used in gene expression studies, is 1.6% tryptone, 1% yeast extract and 0.5% NaCl. Basal salts medium (BSM-glucose) contained the following (per liter): phosphate buffer 100 mmol (pH 7.2); glucose, 20 g; NH_4Cl , 2 g; $MgCl_2 \cdot 6H_2O$, 644 mg; $MnCl_2 \cdot 4H_2O$, 1 mg; nitriloacetic acid, 25 0.1 g; $FeCl_2 \cdot 4H_2O$, 2.6 mg; $Na_2B_4O_7 \cdot 10H_2O$, 0.1 mg; $CuCl_2 \cdot 2H_2O$, 0.15 mg; $Co(NO_3)_2 \cdot 6H_2O$, 0.125 mg; $ZnCl_2$, 2.6 mg; $CaCl_2 \cdot 2H_2O$, 33 mg; $(NH_4)_6Mo_7O_{24} \cdot 4H_2O$, 0.09 mg; and EDTA, 1.25 mg. When required the sulfur source was either 2 mM $MgSO_4$, 300 μM Dibenzothiophene (DBT), 300 μM Dibenzothiophene sulfone

(DBTO₂) or 300 μ M 2-(2-hydroxyphenyl) benzenesulfinate (HPBS). For solid media, agar or agarose was added at a concentration of 1.5% (wt/wt). The antibiotic concentrations for *E. coli* were as follows: ampicillin, 100 μ g/ml; kanamycin, 30 μ g/ml; tetracycline, 10 μ g/ml.

DNA Methods

Restriction enzymes and T4 DNA ligase were purchased from New England Biolabs, Inc. (Beverly, MA) and used as recommended by the supplier. Chromosomal DNA was isolated 10 by the method described by Woo et al., *BioTechniques* **13**: 696-698 (1992). Small scale plasmid preparations from *E. coli* were carried out as described by Birboim and Doly, *Nuc. Acids Res.* **7** : 1513-1523 (1979). Larger scale DNA preparations were carried out with Midi-prep columns from 15 Qiagen (Chatsworth, CA). DNA fragments were purified from agarose gels after electrophoretic separation by the method of Vogelstein and Gillespie (*Proc. Natl. Acad. Sci. USA* **76**: 615-619 (1979)). DNA fragments were cloned into vectors by using techniques described by Sambrook et al.

20 Degenerate oligonucleotide probes were end-labeled using standard digoxigenin protocols according to the Boehringer Mannheim DIG Oligonucleotide 3'-End Labeling Kit (Cat. No. 1362372). Hybridization was performed in 5X SSC with blocking solution containing 50% ultrapure deionized 25 formamide at 42°C overnight (16 hr). Detection of hybrids was by enzyme immunoassay according to the Boehringer Mannheim Nonradioactive DIG DNA Labeling and Detection Kit (Cat. No. 1093657).

DNA samples were sequenced by SeqWright (Houston, TX) 30 using a dye-terminator cycling sequencing kit from Perkin Elmer and the 373A and 377 ABI automatic DNA sequencer. The sequence was extended by synthesizing overlapping

oligonucleotides to previously read sequence. The synthesized oligonucleotides were used as primers for continuing sequence reactions. Sequencing reads were assembled and edited to 99.99% accuracy using Genecode's

5 *Sequencher*, version 3.0 computer software.

DNA and protein sequence analysis was performed with the MacVector software program (Oxford Molecular Group, Campbell, CA). Nucleotide and amino acid sequences were compared to sequences in the available databases using 10 BLAST. The Wisconsin Genetics Computer Group (GCG) software (Devereux et al., *Nucl. Acids Res.* **12** : 387-395 (1984)) program GAP was used to generate comparisons of the protein sequences.

15 Transformation of *E. coli*

Plasmid DNA was introduced into *E. coli* DH10 β by electroporation. Competent ElectroMAX DH10 β (Gibco-BRL, Gaithersburg, MD) were used according to the manufacturer's suggestions.

20 Preparation of cell-free extracts

Cells grown in the appropriate medium were concentrated to an optical density at 600 nm of 50 by centrifugation and resuspended in 10 mM phosphate buffer (pH 7.0). Cells were disrupted in a French press and 25 debris was removed by centrifugation at 32,000 x g for 20 min. Cell lysates were stored on ice at 4°C.

Desulfurization assays and analytical analysis

HPBS desulfurase activity was assayed by the ability of cell-free lysates to convert HPBS (substrate) to 2-HBP (product) in a one hour assay at 30°C. The amounts of product made and substrate consumed during the reaction

were quantitated by high-pressure liquid chromatography (HPLC) analysis. HPBS desulfinase activity was also measured by fluorescence spectroscopy. In a typical enzyme assay, enzyme activity is determined by the change in 5 fluorescence at an excitation wavelength of 288 nm and an emission wavelength of 414 nm as HPBS is converted to 2-HBP. The assay is initiated by the addition of 20 - 100 µg total protein to a 3 mL solution of 200 µM HPBS in 50 mM phosphate buffer pH 7.5 containing 0.1 M NaCl.

10 Expression studies

E. coli DH10 β harboring the *Sphingomonas dszB* overexpression plasmid pDA296 was inoculated into 100ml of 2YT medium containing ampicillin and allowed to grow with shaking at 30°C. At an OD₆₀₀ of approximately 0.3, the 15 culture was divided into two parts. One half of the culture was induced by the addition of isopropylthio- β -galactoside (IPTG) (final conc. 1 mM) and the remaining culture was used as an uninduced control (no IPTG was added). Following incubation for an additional 3 hr, both 20 cultures were harvested and cell-free lysates were prepared.

Protein purification and N-terminal sequencing

Sphingomonas AD109 cell paste was resuspended in an approximately equal weight of 25 mM phosphate buffer pH 7.5 25 containing 0.1 mM EDTA, 0.5 mM dithiothreitol (DTT), 10 µg/mL DNase and 1 mM phenylmethylsulfonyl fluoride and passed through a French press mini-cell at about 20,000 psi. Cell debris was removed by centrifugation and the cell lysate was fractionated over an Econo-Pac High Q 30 cartridge manufactured by Bio-Rad. A linear 0-0.5 M NaCl gradient was used to elute the bound protein into

fractions. The active fractions were identified by a 2-HBP fluorescence enzyme assay (excitation/emission wavelengths set at 288/414 nm). The active fractions were pooled and desalted over a Bio-Rad P6 gel filtration cartridge,
5 diluted to 1.7 M ammonium sulfate and fractionated over a Phenyl Superose HR 5/5 column manufactured by Pharmacia. A linear 1.7-0.0 M ammonium sulfate gradient was used to elute protein into fractions. Active fractions were identified and pooled as described above. Identity and
10 purity of the AD109 HPBS desulfinase protein was also determined by SDS-PAGE and Western blots using antibodies generated against the DszB protein from *Rhodococcus erythropolis* strain IGTS8. N-terminal microsequencing of the HPBS desulfinase was carried out by Edman degradation
15 after transfer of the purified protein to a polyvinylidene difluoride (PVDF) membrane.

SDS-PAGE and Western Blot Analysis

Protein separations were done with Novex (San Diego, CA) precast 10% polyacrylamide gels with Tris-Glycine-sodium dodecyl sulfate (SDS) (Laemmli) running buffer.
20 Western blot analysis was carried out by first transferring the proteins electrophoretically to nitrocellulose membranes as recommended by Biorad (Hercules, CA). Blots were treated with antisera raised against the purified
25 IGTS8 DszB protein (primary antibody) and then with goat anti-rabbit antisera conjugated to horseradish peroxidase as the secondary antibody. Finally, the proteins were detected with a horseradish peroxidase catalyzed chemiluminescent reaction.

Example 1 Soil enrichments and isolation of a
 microorganism that can use HPBS as a sole
 sulfur source

5 Three independent soil samples from oil-contaminated sites were used to perform soil enrichments for microorganisms able to use HPBS as a sole sulfur source. Approximately 5 grams of each soil sample was placed into a sterile 250 ml flask along with 50 ml of BSM Glucose medium 10 containing HPBS (300 μ M) as the sole source of sulfur. Following incubation for 96 hrs at 30°C, a 3 ml sample of each enrichment was transferred to fresh BSM Glucose medium containing HPBS. After 72 hrs, one of the three flasks (flask #3) showed visible turbidity, while the two 15 remaining flasks showed no visible increase in turbidity (even after more than a week of incubation). Microscopic analysis of the contents of flask #3 revealed the presence of a mixed population of bacterial cells (i.e., sessile and motile rods of varying shapes; large and small coccoid 20 shaped bacteria). After repeated liquid subculture enrichments with HPBS as the sole sulfur source, the contents of the flask was plated onto several RM and LB agar plates. Following incubation at 30°C, a variety of 25 microorganisms with different colony morphologies was present. Analysis of individual colonies from these plates identified a pure isolate that efficiently used HPBS as a sole sulfur source. This strain, designated AD109, was selected for further analysis.

Example 2 Characterization and identification of
30 strain AD109

The HPBS utilizing strain AD109 is a Gram-negative, motile rod that forms distinctive yellow colonies on agar plates. It grows somewhat poorly on LB agar, but grows

rather well on RM agar plates. Like *Rhodococcus* IGTS8, strain AD109 also has the ability to produce clearing zones on a BSM Glucose DBT-sulfone plate. The optimal growth temperature of AD109 was found to be between 30 and 37°C.

5 Based on fatty acid analysis (Acculab, Inc., Newark, DE), this strain was identified as a *Sphingomonas* species. Strain AD109 was a "good" match to *S. paucimobilis* (formerly *Pseudomonas paucimobilis*) based on its 10 "similarity index". The similarity index is a mathematical expression of the extent to which the fatty acid profile of a given unknown matches the mean profile for an organism in the TSBA database. Strain AD109 had an index value of 0.426 which indicates that it is from a strain of a species that differs significantly from those represented in the 15 database. A similarity index of 0.5 or above is considered to be an "excellent" match (a value of 1.0 being the highest possible). On the other hand, an index below 0.3 indicates that the sample is from a species that is not likely to be in the database. Based on 16S rRNA sequence 20 analysis and the presence of sphingoglycolipids, Yabuuchi et al. (*Microbiol. Immunol.* **34** : 99-119 (1990)) proposed that *P. paucimobilis* be reclassified and placed into the genus *Sphingomonas*.

25 Example 3 Growth characteristics of *Sphingomonas* species strain AD109

Evidence for the existence of an HPBS desulfinase activity was demonstrated by monitoring the supernatant of a AD109 culture growing in BSM Glucose HPBS (300 μM). By 30 the time the culture was well into stationary phase all of the HPBS had been converted with no apparent accumulation of identifiable intermediates. There was, however, a

transient production of a small amount of 2-HBP, as determined by HPLC analysis, which also disappeared with time. This preliminary result suggested that AD109 may also be capable of metabolizing 2-HBP. *Sphingomonas* strain

5 AD109 was also capable of utilizing DBT-sulfone ($DBTO_2$) as a sole sulfur source. The ability to utilize DBT-sulfone as a sole sulfur source suggests that strain AD109 may also contain a gene that encodes DBT-sulfone monooxygenase activity.

10 During the course of growth studies it was discovered that strain AD109 could utilize DBT as a sole sulfur source. While growing with DBT, however, the culture supernatant takes on a very characteristic orange/brown color with an absorption maximum of approximately 470 nm.

15 Orange-colored oxidation products have been previously identified in a number of *Pseudomonas* species that are capable of degrading DBT (Monticello et al., *Appl. Environ. Microbiol.* **49** : 756-760 (1985)); Foght and Westlake, *Can. J. Microbiol.* **36** : 718-724 (1990)). No such color development was detected in cultures growing with either HPBS or DBT-sulfone as sulfur sources.

Example 4 Demonstration of HPBS desulfinase activity
 in AD109 cell-free lysates

A cell-free lysate prepared from a culture of
25 *Sphingomonas* strain AD109 (grown in BSM Glucose medium containing HPBS) was used in a time course study to examine the rate at which HPBS is converted to 2-HBP. As presented in Figure 4, at a protein concentration of 4 mg/ml there was a linear increase in 2-HBP production and a concomitant disappearance of HPBS.
30

The product of the *in vitro* reaction was confirmed to be 2-HBP by a spectral comparison to authentic 2-HBP. The ultraviolet absorption spectrum of the suspected 2-HBP peak produced by the action of the AD109 lysate is virtually identical with that of the 2-HBP standard. Furthermore, the molecular weight of the unknown compound was exactly that of authentic 2-HBP as determined by GC-MS analysis.

Example 5 Purification of the HPBS desulfinase from
Sphingomonas AD109

HPBS desulfinase was purified from AD109 by a series of chromatographic steps using a Bio-Rad low pressure column chromatography Econo system and a Pharmacia FPLC (Gray *et al.*, *Nature Biotech.* **14** : 1705-1709 (1996)). The steps included fractionation over an anion exchange resin followed by a hydrophobic interaction column chromatography step. These protein purification steps are described above. A 15-20 fold purification was achieved in these two steps which is comparable to protein preparations from a *Rhodococcus* IGTS8 lysate.

The molecular weight of this protein by SDS-PAGE was estimated to be 40,000 daltons, which is approximately the same size as DszB purified from IGTS8. Western analysis demonstrated that the purified protein shows some cross-reactivity with anti-DszB antisera.

Nonlinear regression analysis of an enzyme progress curve was performed according to the general method described by Duggleby, *Methods Enzymol.* **249** : 61-90 (1995). The analysis involves fitting the integrated Michealis-Menton rate equation $V_m^*t = y - K_m^* \ln(1 - y/[A]_0)$ to concentration vs. time data from the enzyme catalyzed reaction of 2-(2-phenyl)benzenesulfinate to 2-

hydroxybiphenyl monitored to completion by fluorescence. The semi-pure protein sample was generated by fractionation of a crude lysate over Q Sepharose Fast Flow resin (Pharmacia) by a linear 0-0.5 M NaCl gradient, as discussed 5 in more detail above. The purity of the active fraction was determined by SDS-PAGE. Pure enzyme is not necessary for the application of enzyme progress curve analysis, however, the calculation of k_{cat} ($V_m = [E]_t^*k_{cat}$) was limited to a value range as only a crude estimate of the enzyme 10 concentration was available. The reaction conditions were as follows. A 3 mL reaction solution containing 1 μ M HPBS and 0.1 M NaCl in 50 mM phosphate at pH 7.5 and 30°C was initiated by the addition of 0.023 mg total protein and was monitored for 30 min by fluorescence at an excitation 15 wavelength of 288 nm and an emission wavelength of 414 nm. The data were fit to the equation using the Kaleidagraph data analysis/graphics application (Abelleck Software).

Based on the kinetic parameters calculated from the enzyme progress assay ($K_m=0.3 \mu$ M and $V_m=0.1 \mu$ M/min), the 20 minimum $k_{cat} = 0.5 \text{ min}^{-1}$. However, a more realistic value would be on the order of 2 min^{-1} in view of the fact that the preparation is estimated to be about 25% pure. Therefore, the HPBS desulfinase from *Sphingomonas* AD109 appears to be comparable to that from *Rhodococcus* IGTS8 25 with the possibility of a higher catalytic efficiency (k_{cat}/K_m).

The N-terminal amino acid sequence of the purified *Sphingomonas* HPBS desulfinase was also determined. Protein microsequencing using standard methods of analysis resulted 30 in the following amino acid sequence:

1	10	20
TTDIHPASAA	SSPAARATIT	YS (SEQ ID NO.: 7)

A comparison of the putative AD109 HPBS desulfinase N-terminal sequence with that of the N-terminus of the IGTS8 DszB protein revealed that 9 out the 22 amino acid residues were identical (41%). In order to determine whether the purified protein is, in fact, the *Sphingomonas* desulfinase protein, a degenerate (192 permutations) 17-mer oligonucleotide probe with the following sequence: 5' ACN GAY ATH CAY CCN GC 3' (SEQ ID NO.: 8), was designed based on the determined N-terminal sequence. Following labeling with a non-isotopic label this probe was used in hybridization studies using the cloned *Sphingomonas* AD109 HPBS desulfinase gene (see below) and the *dszB* gene from IGTS8 (Denome et al., *J. Bacteriol.* 176 : 6707-6716 (1994); Piddington et al., *App. Environ. Microbiol.* 61 : 468-475 (1995)). The labeled oligonucleotide probe hybridized to the cloned *Sphingomonas* HPBS desulfinase gene which indicated that the correct protein had been purified. However, no signal was detected in the lane containing a fragment harboring the *Rhodococcus* *dsz B* gene.

20 Example 6 Cloning of the *Sphingomonas* AD109 HPBS
desulfinase gene

Strain AD109 has been shown to be capable of using HPBS as a sole sulfur source and clearing a DBTO₂ plate. On the assumption that the gene(s) responsible for DBTO₂ clearing and HPBS desulfinase activity are genetically closely linked, as they are in *Rhodococcus* IGTS8, a cloning scheme was devised to isolate the HPBS desulfinase gene from *Sphingomonas* strain AD109. Total genomic DNA from strain AD109 was digested with either EcoRI, BamHI, and 30 HindIII and the resulting fragments were ligated into pUC18

or pSL1180. Following transformation of *E. coli* DH10 β , approximately 1000-2000 Lac-negative, ampicillin-resistant colonies of each library were screened for the ability to clear a DBTO₂ plate. No clearing colonies were detected
5 amongst transformants derived from either the EcoRI or BamHI libraries. However, two clearing colonies were detected utilizing the HindIII library and one clearing colony was detected with the NotI library. Based on restriction endonuclease profiles, both colonies from the
10 HindIII library contained the same large fragment (~20 kb). Furthermore, there was measurable HPBS desulfinase activity in cell-free lysates of these strains.

The single clearing colony from the NotI library contained a 6.5 kb fragment which, according to restriction
15 endonuclease mapping, overlapped the 20 kb HindIII fragment. This clone also contained measurable HPBS desulfinase activity.

Subcloning analysis localized the genes responsible for DBTO₂ clearing and HPBS desulfinase activity to a 6 kb
20 HindIII-NotI fragment. A smaller 2.7 kb HindIII-SmaI fragment was subsequently found to retain HPBS desulfinase activity, but lost the ability to clear a DBTO₂ plate. It is likely, therefore, that the gene that confers the ability to produce clearing zones on a DBT-sulfone plate
25 spans the SmaI site.

Example 7 DNA sequence analysis of the *Sphingomonas* sp. strain AD109 desulfurization gene cluster

The nucleotide sequence of a 4144 bp region which
30 encompasses the AD109 HPBS desulfinase gene was

determined from both DNA strands and is present in Figure 6 (SEQ ID NO.: 12). The overall G+C content of the first 3837 base pairs of the AD109 sequence is 64.5%, a value which is consistent with the range of G+C values (61.7 - 67.2%) reported for various *Sphingomonas* species (Yabuuchi et al. (1990)). A comparison of the AD109 nucleotide sequence with the IGTS8 *dsz* sequence by DNA matrix analysis revealed that a considerable amount of homology exists between the two sequences as evidenced by the presence of a near continuous diagonal line.

Open reading frame analysis of the AD109 sequence revealed the presence of a number of ORFs on both DNA strands, but of these, only three contained the codon-choice pattern characteristic of microorganisms with G-C rich genomes (West et al., *Nucl. Acids Res.* **16**: 9323-9334 (1988)). All three identified ORFs were in the same transcriptional orientation. A strong preference for codons with either G or C occurred in positions 1 and 3. The first codon position of all three ORFs ranged from 67 to 72%, while the third codon position of all three ORFs ranged from 79-81%. In addition, the predicted translation initiation sites of all three ORFs are preceded by sequences that resemble a consensus ribosome binding site.

The entire nucleotide sequence of the AD109 region was used to conduct a BLAST search of the available DNA databases. The *Rhodococcus* IGTS8 *dsz* genes were the highest scoring sequences that demonstrated homology to the *Sphingomonas* sequences. The only other nucleotide sequence that demonstrated any significant homology to the *Sphingomonas* DNA, was the *Streptomyces pristinaespiralis* *snaA* gene which encodes the large

subunit of the PII_A synthase (Blanc et al., *J. Bacteriol.* 177 : 5206-5214 (1995)). The *Sphingomonas dszA* and *S. pristinaespiralis snaA* genes demonstrate about 60% identity over a 800 bp region proximal to the 5' end of each gene.

The first ORF (bp 442-1800; Figures 1A-1D) is 71% identical (at the nucleotide level) to the *Rhodococcus dszA* gene. The primary translation product of ORF-1 would encode a protein (*Sphingomonas DszA* or *Dsz(S)*) that contains 453 amino acids with a predicted molecular weight of 50,200. More importantly, this protein demonstrates considerable homology to the amino acid sequence of *Rhodococcus DszA* (*Dsz(R)*, SEQ ID NO.: 9) over the entire length of the polypeptide (76% identity and 87% similarity; Figure 8). The protein databases were also searched with the *Sphingomonas DszA* protein sequences. Aside from the *DszA* protein of *Rhodococcus IGTS8*, several other proteins demonstrated significant homology to the *Sphingomonas DszA* protein. These include a hypothetical 49.3 kD protein in the IDH-DEOR intergenic region of *Bacillus subtilis* which showed 45% identity over 382 residues, the PII_A synthase SnaA subunit of *S. pristinaespiralis* (Blanc et al., *J. Bacteriol.* 177 : 5206-5214 (1995)) which was 49% identical over 358 residues and the nitrilotriacetate monooxygenase of *Chelatobacter heintzii* (Xu et al., Abstracts of the 95th General Meeting of the American Society for Microbiology, Q-281) which was 50% identical over the 335 residues examined.

30 The stop site of the *Sphingomonas* ORF-1 shows a 4-bp overlap with the translation start site of the second ORF (bp 1800-2906; Figures 2A-2C), which shows a

high degree of homology to the *Rhodococcus* IGTS8 *dszB* gene (67% identity). It was determined that the primary translation product of ORF-2 would encode a 369-amino acid polypeptide with a predicted molecular weight of 5 40,000 (*Sphingomonas* DszB or Dsz(S)). At the amino acid level this putative protein is 66% identical (75% similarity) to the *Rhodococcus* HPBS desulfinase protein DszB (DszB(R), SEQ ID NO: 10), as shown in Figure 9. Except for the IGTS8 DszB protein, a BLAST search with 10 the *Sphingomonas* DszB sequence did not identify any other significant homologous sequences in the available databases. The predicted N-terminus of the *Sphingomonas* DszB protein matches identically the N-terminus of the HPBS desulfinase purified from AD109 cell lysates, 15 except that the amino-terminal methionine was absent. Removal of the methionine residue has been shown to occur when the second amino acid is Ala, Ser, Gly, Pro, Thr or Val (Hirel et al., *Proc. Nat. Acad. Sci. USA* **86** : 8247-8251 (1989)).

20 The stop site of the *Sphingomonas* *dszB* gene also shows a 4-bp overlap with the translation start site of the third ORF. This ORF (bp 2906-4141; Figures 3A-3C), shows significant homology to the *Rhodococcus* IGTS8 *dszC* gene. For example, over the first 931 bp, this ORF is 25 69% identical to the IGTS8 *dszC* gene and the N-terminus of the protein predicted by this sequence (*Sphingomonas* DszC, DszC(S)) is 67% identical to the N-terminus of *Rhodococcus* DszC (DszC(R), SEQ ID NO: 11), as shown in Figure 10. A BLAST search of the protein databases with 30 the available *Sphingomonas* DszC sequence identified a number of proteins in addition to the IGTS8 DszC protein. The *Sphingomonas* DszC protein is 32% identical

(over 199 residues) to Isobutylamine N-Hydroxylase (IBAH) of *Streptomyces viridifaciens*. It has previously been shown that IBAH exhibits the greatest similarity to the IGTS8 DszC protein (Parry et al., *J. Bacteriol.*, 5 179: 409-416 (1997)). In addition, the AD109 DszC protein showed variable homology to a number of acyl coenzyme A dehydrogenases. For example, the N-terminal 300 residues of the *Sphingomonas* DszC protein is 29% identical to the acyl CoA dehydrogenase of *B. subtilis*.

10 The sequences (400 bp) directly upstream of the *dszA* start site contain regulatory elements (i.e., promoter elements) that control transcription of the AD109 *dsz* gene cluster. A comparison of this potential promoter region with the IGTS8 *dsz* promoter region failed to reveal any significant homology. It has been shown that the IGTS8 *dsz* promoter region encompasses a region of potential diad symmetry that may contain an operator (Li et al., *J. Bacteriol.* 15 178 : 6409-6418 (1996)). An examination of the AD109 sequences directly 15 upstream of *dszA* revealed no such palindromic sequence.

20

Example 8 Expression of the *Sphingomonas dszB* gene
 in *E. coli*

The AD109 *dszB* gene was subcloned into the tac promoter expression vector, pEBCtac, in two steps. The 25 first step involved cloning a 1.2 kb *PstI-BglII* fragment that contained the entire coding region of the AD109 *dszB* gene (Figures 2A-2C) into the polylinker plasmid pOK12. The resulting plasmid, designated pDA295, contained a unique *XbaI* site upstream of the *dszB* gene.

In the second step, a 1.2 kb *Xba*I-*Bgl*II fragment from pDA295 that contained the entire *dszB* gene was cloned into the *Xba*I and *Bgl*II sites of pEBCtac, thus placing the AD109 *dszB* gene under the transcriptional control of 5 the tac promoter. This plasmid, designated pDA296 and presented in Figure 7, was introduced into *E. coli* DH10 β for expression studies.

HPBS desulfinase assays (2 mg/ml protein) using cell-free lysates prepared from induced and uninduced 10 cultures of DH10 β /pDA296 were performed. In the absence of IPTG the cell-free lysate contained very little HPBS desulfinase activity. Only 22 nmoles of 2-HBP were produced during the 60 min. incubation period which corresponds to a specific activity of 0.2 (nmoles 2-HBP 15 formed/min/mg protein). The lysate prepared from the IPTG-induced culture, however, had approximately 20 times more HPBS desulfinase activity (4.2 nmoles 2-HBP formed/min/mg protein) than the lysate prepared from the uninduced culture.

20 EQUIVALENTS

Those skilled in the art will know, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. These and all other 25 equivalents are intended to be encompassed by the following claims.

CLAIMS

We claim:

1. A culture of *Sphingomonas* sp. strain AD109 or a mutant thereof.
- 5 2. A nucleotide molecule encoding an enzyme having an amino acid sequence set forth in SEQ ID NO.: 2; or a mutant, fragment or homologue thereof.
3. The nucleotide molecule of Claim 2 having substantially the same sequence as the sequence set forth in SEQ ID NO.: 1.
- 10 4. A nucleotide molecule encoding an enzyme having an amino acid sequence set forth in SEQ ID NO.: 4; or a mutant, fragment or homologue thereof.
5. The nucleotide molecule of Claim 4 having substantially the same sequence set forth in SEQ ID NO.: 3.
- 15 6. A nucleotide molecule encoding an enzyme having an amino acid sequence set forth in SEQ ID NO.: 6; or a mutant, fragment or homologue thereof.
- 20 7. The nucleotide molecule of Claim 6 having substantially the same sequence as the sequence set forth in SEQ ID NO.: 5.
8. A nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO.: 1, SEQ ID NO.: 3, 25 or SEQ ID NO.: 5; a mutant or fragment thereof; or a combination thereof.

9. A nucleotide sequence comprising at least about 20 contiguous nucleotides from the sequence of SEQ ID NO.: 1, or the complement thereof.
10. The nucleotide sequence of Claim 9 comprising at least about 40 contiguous nucleotides from the sequence of SEQ ID NO.: 1 or the complement thereof.
11. The nucleotide sequence of Claim 9 comprising at least about 50 contiguous nucleotides from the sequence of SEQ ID NO.: 1 or the complement thereof.
12. A nucleotide sequence comprising at least about 20 contiguous nucleotides from the sequence of SEQ ID NO.: 3, or the complement thereof.
13. The nucleotide sequence of Claim 12 comprising at least about 40 contiguous nucleotides from the sequence of SEQ ID NO.: 3 or the complement thereof.
14. The nucleotide sequence of Claim 12 comprising at least about 50 contiguous nucleotides from the sequence of SEQ ID NO.: 3 or the complement thereof.
15. A nucleotide sequence comprising at least about 20 contiguous nucleotides from the sequence of SEQ ID NO.: 5, or the complement thereof.
16. The nucleotide sequence of Claim 15 comprising at least about 40 contiguous nucleotides.

17. The nucleotide sequence of Claim 15 comprising at least about 50 contiguous nucleotides.
18. A nucleotide sequence which specifically hybridizes to a polynucleotide molecule comprising the nucleotide sequence set forth in SEQ ID NO.: 1.
- 5 19. The nucleotide sequence of Claim 18, wherein the isolated nucleotide sequence hybridizes to the polynucleotide molecule under conditions of high stringency.
- 10 20. A nucleotide sequence which hybridizes to a polynucleotide molecule comprising the nucleotide sequence set forth in SEQ ID NO.: 3.
21. The nucleotide sequence of Claim 20, wherein the isolated nucleotide sequence hybridizes to the polynucleotide molecule under conditions of high stringency.
- 15 22. A nucleotide sequence which hybridizes to a polynucleotide molecule comprising the nucleotide sequence set forth in SEQ ID NO.: 5.
- 20 23. The nucleotide sequence of Claim 22, wherein the isolated nucleotide sequence hybridizes to the polynucleotide molecule under conditions of high stringency.
24. An enzyme having substantially the amino acid sequence set forth in SEQ ID NO.: 2, or an enzymatically active fragment thereof.
- 25

25. The enzyme of Claim 24, wherein said enzyme is isolated from a microorganism.
26. The enzyme of Claim 25 wherein the microorganism is a *Sphingomonas*.
- 5 27. The enzyme of Claim 26 wherein the microorganism is *Sphingomonas* sp. strain AD109.
- 10 28. The enzyme of Claim 27 having substantially the amino acid sequence set forth in SEQ ID NO.: 2, or fragment thereof, said enzyme being substantially free of other *Sphingomonas* proteins.
29. An enzyme having substantially the amino acid sequence set forth in SEQ ID NO.: 4, or an enzymatically active fragment thereof.
- 15 30. The enzyme of Claim 29, wherein said enzyme is isolated from a microorganism.
31. The enzyme of Claim 30 wherein the microorganism is a *Sphingomonas*.
32. The enzyme of Claim 31 wherein the microorganism is *Sphingomonas* sp. strain AD109.
- 20 33. The enzyme of Claim 32 having a molecular weight of about 40,000 daltons.

34. An enzyme having substantially the amino acid sequence set forth in SEQ ID NO.: 4, or fragment thereof, said enzyme being substantially free of other *Sphingomonas* proteins.
- 5 35. An enzyme having substantially the amino acid sequence set forth in SEQ ID NO.: 6, or an enzymatically active fragment thereof.
36. The enzyme of Claim 35, wherein said enzyme is isolated from a microorganism.
- 10 37. The enzyme of Claim 36 wherein the microorganism is a *Sphingomonas*.
38. The enzyme of Claim 37 wherein the microorganism is *Sphingomonas* sp. strain AD109.
- 15 39. An enzyme having substantially the amino acid sequence set forth in SEQ ID NO.: 6, or fragment thereof, said enzyme being substantially free of other *Sphingomonas* proteins.
40. An enzyme comprising the amino acid sequence set forth in SEQ ID NO.: 2.
- 20 41. An enzyme comprising the amino acid sequence set forth in SEQ ID NO.: 4.
42. An enzyme comprising the amino acid sequence set forth in SEQ ID NO.: 6.
- 25 43. A *Sphingomonas* enzyme catalyzing the conversion of dibenzothiophene to dibenzothiophene-5,5-dioxide.

44. A *Sphingomonas* enzyme catalyzing the conversion of dibenzothiophene-5,5-dioxide to 2-(2-hydroxyphenyl)benzenesulfinate.
45. A *Sphingomonas* enzyme catalyzing the conversion of 2-(2-hydroxyphenyl)benzenesulfinate to 2-hydroxybiphenyl and inorganic sulfur.
46. A plasmid comprising a nucleic acid molecule of Claim 2 operatively linked to a promoter.
- 10 47. A plasmid comprising a nucleic acid molecule of Claim 4 operatively linked to a promoter.
48. A plasmid comprising a nucleic acid molecule of Claim 6 operatively linked to a promoter.
49. A plasmid comprising a nucleotide molecule of Claim 8 operatively linked to a promoter.
- 15 50. A transformed microorganism containing a recombinant DNA plasmid comprising a DNA molecule encoding an enzyme set forth in SEQ ID NO.: 2, a mutant or a homologue thereof.
- 20 51. A transformed microorganism containing a recombinant DNA plasmid comprising a DNA molecule encoding an enzyme having the sequence set forth in SEQ ID NO.: 4, or a mutant, fragment or homologue thereof.

52. A transformed microorganism containing a recombinant DNA plasmid comprising a DNA molecule encoding an enzyme having the amino acid sequence set forth in SEQ ID NO.: 6; or a mutant or
5 homologue thereof.
53. A transformed microorganism containing a recombinant DNA plasmid comprising a DNA sequence encoding an enzyme having the sequence set forth in SEQ ID NO.: 2, or a mutant, fragment or homologue thereof; a DNA sequence encoding an enzyme having the sequence set forth in SEQ ID NO.: 4, or a
10 mutant, fragment or homologue thereof; and a DNA sequence encoding an enzyme having the amino acid sequence set forth in SEQ ID NO.: 6, or a mutant,
15 fragment or homologue thereof.
54. A method of desulfurizing a fossil fuel containing organosulfur molecules, comprising the steps of:
(a) contacting the fossil fuel with an aqueous phase containing a *Sphingomonas*-derived
20 desulfurization biocatalyst thereby forming a fossil fuel and aqueous phase mixture;
(b) maintaining the mixture under conditions sufficient for desulfurization, thereby resulting in a fossil fuel having a reduced
25 organic sulfur content; and
(c) separating the fossil fuel having a reduced organic sulfur content from the resulting aqueous phase.
55. The method of Claim 54 wherein the biocatalyst
30 comprises an enzyme preparation or a microorganism comprising an enzyme having the sequence set forth

in SEQ ID NO.: 2, or a mutant, active fragment or homologue thereof; an enzyme having the sequence set forth in SEQ ID NO.: 4, or a mutant, active fragment or homologue thereof; and an enzyme having
5 the amino acid sequence set forth in SEQ ID NO.: 6, or a mutant, active fragment or homologue thereof.

56. The method of Claim 55 further comprising the steps of adding a flavoprotein, flavin, NADH or a combination thereof.
- 10 57. The method of Claim 55 wherein the fossil fuel is a liquid hydrocarbon.
58. The method of Claim 57 wherein the liquid hydrocarbon is a petroleum.
- 15 59. The method of Claim 55 wherein the biocatalyst is a microorganism.
60. The method of Claim 59 wherein the microorganism is *Sphingomonas* sp. strain AD109.
- 20 61. The method of Claim 59 wherein the microorganism contains a heterologous DNA molecule which encodes the biocatalyst.
62. The method of Claim 61 wherein the heterologous DNA is derived from *Sphingomonas* sp. strain AD109.
63. The method of Claim 55 wherein the biocatalyst is a cell-free fraction.

64. The method of Claim 63 wherein the biocatalyst is a
cell-free fraction of *Sphingomonas* sp. strain
AD109.
65. A method of oxidizing organic molecules, comprising
the steps of:
- 5 (a) contacting the organic molecules with an
aqueous phase containing a *Sphingomonas*-
derived biocatalyst capable of oxidizing
10 organosulfur compounds, thereby forming an
organic compound and aqueous phase mixture;
and
- (b) maintaining the mixture under conditions
sufficient for oxidation of the organic
15 molecules by the biocatalyst, thereby forming
an oxidized organic compound.
66. The method of Claim 65 wherein the biocatalyst
comprises an enzyme having the sequence set forth
in SEQ ID NO.: 2, or a mutant, active fragment or
homologue thereof; an enzyme having the sequence
20 set forth in SEQ ID NO.: 4, or a mutant, active
fragment or homologue thereof; an enzyme having the
amino acid sequence set forth in SEQ ID NO.: 6, or
a mutant, active fragment or homologue thereof; or
a combination thereof.
- 25 67. The method of Claim 66 wherein the organic is an
organosulfur compound which is a component of a
fossil fuel.

68. The method of Claim 67 wherein the organosulfur compound is a substituted or unsubstituted dibenzothiophene and the oxidized organosulfur compound is a substituted or unsubstituted dibenzothiophene-5-5-dioxide.
- 5
69. The method of Claim 67 wherein the organosulfur compound is a substituted or unsubstituted dibenzothiophene-5-5-dioxide and the oxidized organosulfur compound is a substituted or unsubstituted 2-(2-hydroxyphenyl)benzenesulfinate.
- 10
70. The method of Claim 66 wherein the biocatalyst capable of oxidizing organosulfur molecules is a microorganism.
71. The method of Claim 70 wherein the microorganism is *Sphingomonas* sp. strain AD109.
- 15
72. The method of Claim 70 wherein the microorganism contains a heterologous DNA molecule which encodes the biocatalyst.
73. The method of Claim 72 wherein the heterologous DNA is derived from *Sphingomonas* sp. strain AD109.
- 20
74. The method of Claim 66 wherein the biocatalyst capable of oxidizing organosulfur compounds is a cell-free fraction.

75. The method of Claim 74 wherein the biocatalyst is a cell-free fraction of *Sphingomonas* sp. strain AD109.

A *SPHINGOMONAS* BIODESULFURIZATION CATALYST

Abstract of the Disclosure

The invention relates to a novel microorganism, designated *Sphingomonas* sp. strain AD109, which is
5 capable of selectively desulfurizing dibenzothiophene. The invention also includes isolated proteins and nucleic acid sequences obtained from this microorganism.

In another embodiment, the invention provides a method of using this microorganism or enzyme preparations
10 derived therefrom in the biocatalytic desulfurization of a fossil fuel containing organic sulfur compounds.

Sphingamonas ORF1

				50
				*
				*
				*
				60
				*
				*
				*
				70
				*
				80
				*
				90
				*
				100
				*
				110
				*
				120
				*
				130
				*
				140
				*
				150
				*
				160
				*
				170
				*
				180
				*
				190
				*
				200
				*
				210
				*
				220
				*
				230
				*
				240
				*
				250
				*
				260
				*
				270
				*
				280
				*
				290
				*
				300
				*
				310
				*
				320
				*
				330
				*
				340
				*
				350
				*
				360
				*
				370
				*
				380
				*
				390
				*
				400
				*
				410
				*
				420

FIGURE 1A

Sphingomonas ORF1 (cont)

FIGURE 1B

Sphingomonas ORF1 (cont.)

FIGURE 1C

Sphingomonas ORF1 (cont)

ATC CTG CAG CAC CGC CGA CTG TTC CGC ACT GAT TAC GAA GGC CGC ACC CTG CGC AGC CAT I L Q H R G L F R T D Y E G R P I R S H>	1290 * * * * *	1320 * * * * *
CTG GGA CTG CGT GAA CCC GCA TAC CTG GGA GAG TAC GCA TGA L G L R E P A Y L G R Y A * >	1350 * * * * *	

FIGURE 1D

Sphingomonas ORF2

FIGURE 2A

Sphingomonas ORF2 (cont.)

			*	*	*	*	*	*	*	*	*	*	*							
GAT	CCC	TGG	CGG	CAG	ACC	CTG	GTC	GCG	CTG	GGG	ACA	TGG	GAG	GCC	CGT	GCC	TTG	CTG	CTG	AGC
D	P	W	R	Q	T	L	V	A	L	G	T	W	E	A	R	A	L	L	L	S>
			*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
ACG	CTC	GAG	ACG	GCG	GGG	CTT	GGC	GTC	GAC	GGC	GTC	GAG	CTG	ACG	CGC	ATC	GAG	AAC	CCG	
T	L	E	T	A	G	L	G	V	D	V	D	V	E	L	T	R	I	E	N	P>
			*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
TTC	GTC	GAC	GTG	CCG	ACC	GAA	CGA	CTG	CAT	GCC	GCC	GGC	GGC	TCG	CTG	AAA	GGA	ACC	GAC	CTG
F	V	D	V	P	T	E	R	L	H	A	A	G	S	L	K	G	T	D	D	L>
			*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
TTC	CCC	GAC	GTG	CCG	ACC	CAG	CAG	GCC	GCA	GTC	CTT	GAG	GAT	GAG	CGC	GGC	GAC	GCC	CTG	
F	P	D	V	T	S	Q	Q	A	A	V	L	E	D	F	R	A	D	A	L>	
			*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
TTC	GCG	TGG	CTT	CCC	TGG	GGC	GGC	GAG	CTC	GAG	ACC	CGC	ATC	GGT	GCA	CGG	CCG	GTC	CTA	
F	A	W	L	P	W	A	A	E	L	E	T	R	I	G	A	R	P	V	L>	
			*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
GAC	CTC	AGC	GCA	GAC	GCG	AAT	GCC	TAT	GCG	AGC	ACC	TGG	ACG	GTG	AGC	GCC	GAG	CTG		
D	L	S	A	D	D	R	N	A	Y	A	S	T	W	T	V	S	A	E	L>	
			*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
CTG	GAC	CGG	CAG	CCC	GAA	CTG	GTG	CAG	CGG	CTC	GTG	GAT	GCC	GTG	AGC	GCC	GAG	CTG		
V	D	R	Q	P	E	L	V	Q	R	L	V	D	A	V	V	D	A	G	R>	

FIGURE 2B

Sphingomonas ORF2 (cont)

FIGURE 2C

Sphingomonas ORF3

		10	*	20	*	30	*	40	*	50	*	60	*						
ATG	AAC	GAA	CTC	GTC	AAA	GAT	CTC	GGC	CTC	AAT	CGA	TCC	GAT	CCG	ATC	GGC	GCT	GTG	CGG
M	N	E	L	V	K	D	L	G	L	N	R	S	D	P	I	G	A	V	R>
70	*	80	*	90	*	100	*	110	*	120	*								
CGA	CTG	GCC	GCG	CAG	TGG	GGG	GCC	ACC	GCT	GTT	GAT	CGG	GAC	CGG	GCC	GGA	TCG	GCA	
R	L	A	A	Q	W	G	A	T	A	V	D	R	D	R	A	G	G	S	A>
130	*	140	*	150	*	160	*	170	*	180	*								
ACC	GCC	GAA	CTC	GAT	CAA	CTG	CGC	GGC	AGC	CTG	CTG	TCC	CTG	TCC	ATT	CCC	GCC	GCA	
T	A	E	L	D	Q	L	R	G	S	G	L	L	S	I	P	A	A>		
190	*	200	*	210	*	220	*	230	*	240	*								
TAT	GGC	GGC	TGG	GGC	GAC	TGG	CCA	ACG	ACT	CTG	GAA	GTT	ATC	CGC	GAA	GTC	GCA	ACG	
Y	G	G	W	G	A	D	W	P	T	T	L	E	V	I	R	E	V	A	T>
250	*	260	*	270	*	280	*	290	*	300	*								
GTG	GAC	GGA	TCG	CTG	GCG	CAT	CTA	TTC	GGC	TAC	CAC	CTC	GGC	TGC	GTA	CCG	ATG	ATC	GAG
V	D	G	S	I	A	H	I	F	G	Y	H	L	G	C	V	P	M	I	E>
310	*	320	*	330	*	340	*	350	*	360	*								
CTG	TTC	GGC	TCG	GCG	CCA	AAG	GAA	CGG	CTG	TAC	CGC	CAG	ATC	GCA	AGC	CAT	GAT	TGG	
L	F	G	S	A	P	Q	K	E	R	Y	R	Q	I	A	S	H	D	W>	
370	*	380	*	390	*	400	*	410	*	420	*								
CGG	GTC	GGG	AAT	GCG	TCG	AGC	GAA	AAC	AAC	AGC	CAC	GTG	CTC	GAG	TGG	AAG	CTT	GCC	
R	V	G	N	A	S	S	E	N	N	S	H	V	L	E	W	K	L	A	A>

FIGURE 3A

Sphingomonas ORE3 (cont)

	430	440	*	450	*	460	*	470	*	480	*
T	A	V	D	G	F	V	L	N	G	GGC	GGC
ACC	GCC	GTC	GAT	GAT	GGC	TTC	CTC	AAC	GGC	AAG	TTC
R	S	S	D	L	I	V	F	G	A	K	H
	490	500	*	510	*	520	*	530	*	540	*
K	S	S	D	L	T	V	F	G	Q	D	E
AAA	AGC	TCC	GAC	CTG	CTC	ATC	GTG	TTC	GGC	CAG	GAA
A	A	A	V	I	P	T	D	R	A	G	V
	550	560	*	570	*	580	*	590	*	600	*
GCG	ATC	ATC	ACC	GCG	GTG	ATT	CCC	ACC	GAC	CGG	GGT
A	I	I	T	A	V	I	P	T	D	R	A
	610	620	*	630	*	640	*	650	*	660	*
CGC	GCA	ATC	GGG	ATG	CGC	CAG	ACC	GAC	AGC	GCC	GAA
R	A	I	G	M	R	Q	T	D	S	A	E
	670	680	*	690	*	700	*	710	*	720	*
TAC	CCA	GAC	GAG	ATC	TTG	GGG	GCA	CCA	AAC	TCA	GTC
Y	P	D	E	I	L	G	A	P	N	S	V
	730	740	*	750	*	760	*	770	*	780	*
CGC	GGC	AGC	CTG	TGG	ACG	CCG	ATT	CAG	TCG	ATC	TTC
R	G	S	L	W	T	P	A	I	Q	S	I
	790	800	*	810	*	820	*	830	*	840	*
GCG	CGT	GGC	GGC	CTC	GAG	GCG	GCA	GCG	GAT	TAC	ACC
A	R	G	A	L	E	A	A	D	Y	T	R

FIGURE 3B

FIGURE 3C




FIGURE 4

200 bp




FIGURE 5

Sphingomonas dsz sequence

10	20	30	40	50	60
*	*	*	*	*	*
GGTCGAGAT CGATCTGACC GTCGAACCCG GCGCGGTTCA AACCATCCTC TGGGGCCTCT					
CCAAGCTCTA GCTAGACTGG CAGCTTGGGC CGCGCCAAGT TTGGTAGGAG ACCCCGGAGA					
70	80	90	100	110	120
*	*	*	*	*	*
TCTTGCACTT GACATAGGAA TCTCTACTAA ATAAATAGAT ATTTATTCTGA CACTAAGTTC					
AGAACGTGAA CTGTATCCTT AGAGATGATT TATTTATCTA TAAATAAGCT GTGATTCAAG					
130	140	150	160	170	180
*	*	*	*	*	*
GGTGATCAGG CCGACCGTGT GTCTCAAGTG CTCGCTCCGG GTGCCACGA GCTAAAGCGC					
CCACTAGTCC GGCTGGCAC A CAGAGTCAC GAGCGAGGCC CAACGGTGT CGATTTCGCG					
190	200	210	220	230	240
*	*	*	*	*	*
GCGATGCTGG GGCACAGCG CTAGGCATTG CGTTCCCTCA CACCAATGAT GAGATGATAC					
CGCTACGACC CCGCTGTCGC GATCCGTAAC GCAAGGGAGT GTGGTTACTA CTCTACTATG					
250	260	270	280	290	300
*	*	*	*	*	*
GATGCGCATG ACCACTATCC GCACCTAGCA CGAAAAGATCC GTGCATTTCG CGAATGCCAA					
CTACGCGTAC TGGTGATAGG CGTGGATCGT GCTTTCTAGG CACGTAAAGC GCTTACGGTT					
310	320	330	340	350	360
*	*	*	*	*	*
TGAAGAGGAC CGACGTACGG CAGCTCCTA CGCTTTCGCG CCATCGTTCA TAGCCAAGGT					
ACTTCTCCTG GCTGCATGCC GTCGAAGGAT GCGAAAGCGC GGTAGCAAGT ATCGGTTCCA					
370	380	390	400	410	420
*	*	*	*	*	*
CTTTTCGACG CCGGTTCGCG TGGCGACTG ACGGCGGTAG CGCCGCGACT ATTGTTTCA					
AAAAAGCTGC GGCCAAGCGC ACCCGCTGAC TGCCGCCATC GCGGCGCTGA TAAGCAAAGT					
430	440	450	460	470	480
*	*	*	*	*	*
AACTCACGAG GATAAGAGCC TATGACCGAT CCACGTCAGC TGACCTGGC CGGATTCTTC					
TTGAGTGCTC CTATTCTCGG ATACTGGCTA GGTGCAGTCG ACGTGGACCG GCCTAAGAAG					
490	500	510	520	530	540
*	*	*	*	*	*
TGTGCCGGCA ACGTCACGCA CGCCCACGGA GCGTGGCGCC ACGCCGACGA CTCCAACGGC					
ACACGGCCGT TGCAGTGCCT GCGGGTGCCT CGCACCGCGG TGCAGTGCCT GAGGTTGCCG					
550	560	570	580	590	600
*	*	*	*	*	*
TTCCTCACCA AGGAGTACTA CCAGCAGATT GCCCGCACGC TCGAGCGCGG CAAGTTCGAC					
AAGGAGTGTT TCCTCATGAT GGTCGTCTAA CGGGCGTGCAG AGCTCGCGCC GTTCAAGCTG					

FIGURE 6A

Sphingomonas dsz sequence (page 2)

610	620	630	640	650	660
*	*	*	*	*	*
CTGCTGTTCC TTCCCGACGC GCTGCCGTG TGGGACAGCT ACGGCGACAA TCTGGAGACC					
GACGACAAGG AAGGGCTGCG CGAGCGGCAC ACCCTGTCGA TGCCGCTGTT AGACCTCTGG					
670	680	690	700	710	720
*	*	*	*	*	*
GGTCTGCGGT ATGGCGGGCA AGGCGCGGTG ATGCTGGAGC CCGCGTAGT TATCGCCGCG					
CCAGACGCCA TACCGCCCCGT TCCGCGCCAC TACGACCTCG GGCGCATCA ATAGCGGC					
730	740	750	760	770	780
*	*	*	*	*	*
ATGGCCTCGG TGACCGAAC A TCTGGGCTG GGCGCCACCA TTTCCACCCAC CTACTACCCG					
TACCGGAGCC ACTGGTTGT AGACCCCGAC CCGCGGTGGT AAAGGTGGTG GATGATGGC					
790	800	810	820	830	840
*	*	*	*	*	*
CCCTACCATG TAGCCCGGGT CGTCGCTTCG CTGGGACCAGC TGTCTCCGG GCGAGTGT					
GGGATGGTAC ATCGGGCCCA GCAGCGAAC GACCTGGTCG ACAGGAGGCC CGCTCACAGC					
850	860	870	880	890	900
*	*	*	*	*	*
TGGAACGTGG TCACCTCGCT CAGCAATGCA GAGGCGCGCA ACTTCGGCTT CGATGAACAT					
ACCTTGCACC AGTGGAGCGA GTCGTTACGT CTCCGCGCGT TGAAGCCGAA GCTACTTGTA					
910	920	930	940	950	960
*	*	*	*	*	*
CTCGACCACG ATGCCCGCTA CGATCGCGCC GATGAATTCC TCGAGGTCTGT GCGCAAGCTC					
GAGCTGGTGC TACGGGCGAT GCTAGCGCGG CTACTTAAGG AGCTCCAGCA CGCGTTCGAG					
970	980	990	1000	1010	1020
*	*	*	*	*	*
TGGAACAGCT GGGATCGCGA TGCGCTGACA CTCGACAAGG CAACCGGCCA GTTCGCCGAT					
ACCTTGTGCA CCCTAGCGCT ACGCGACTGT GAGCTGTTCC GTTGGCCGGT CAAGCGGCTA					
1030	1040	1050	1060	1070	1080
*	*	*	*	*	*
CCGGCTAAGG TGCCTACAT CGACCACCGC GCGGAATGGC TCAACGTACG CGGGCCGCTT					
GGCCGATTCC ACGCGATGTA GCTGGTGGCG CCGCTTACCG AGTTGCATGC GCCCGGGCAA					
1090	1100	1110	1120	1130	1140
*	*	*	*	*	*
CAGGTGCCGC GCTCCCCCCA GGGCGAGCCT GTCATTCTGC AGGCCGGGCT TTCGGCGCGG					
GTCCACGGCG CGAGGGGGGT CCCGCTCGGA CAGTAAGACG TCCGGCCCGA AAGCCGCGCC					
1150	1160	1170	1180	1190	1200
*	*	*	*	*	*
GGCAAGCGCT TCGCCGGCG CTGGGCGGAC GCGGTGTTCA CGATTCGCC CAATCTGGAC					
CCGTTCGCGA AGCGGCCGC GACCCGCGCTG CGCCACAAAGT GCTAAAGCGG GTTAGACCTG					

FIGURE 6B

Sphingomonas dsz sequence (page 3)

1210	1220	1230	1240	1250	1260
*	*	*	*	*	*
ATCATGCAGG CCACGTACCG CGACATAAAG GCGCAGGTCG AGGCCGCCGG ACGCGATCCC					
TAGTACGTCC GGTGCATGGC GCTGTATTTC CGCGTCCAGC TCCGGCGGCC TGCGCTAGGG					
1270	1280	1290	1300	1310	1320
*	*	*	*	*	*
GAGCAGGTCA AGGTGTTTC CGCGGTGATG CCGATCCTCG GCGAGACCGA GGCGATCGCC					
CTCGTCCAGT TCCACAAACG GCGCCACTAC GGCTAGGAGC CGCTCTGGCT CCGCTAGCGG					
1330	1340	1350	1360	1370	1380
*	*	*	*	*	*
AGGCAGCGTC TCGAATAACAT AAATTCGCTG GTGCATCCCG AAGTCGGGCT TTCTACGTTG					
TCCGTGCGAG AGCTTATGTA TTTAAGCGAC CACGTAGGGC TTCAGCCGA AAGATGCAAC					
1390	1400	1410	1420	1430	1440
*	*	*	*	*	*
TCCAGCCATG TCGGGGTCAA CCTTGCCGAC TATTGCGCTCG ATACCCCGCT GACCGAGGTC					
AGGTCGGTAC AGCCCCAGTT GGAACGGCTG ATAAGCGAGC TATGGGGCGA CTGGCTCCAG					
1450	1460	1470	1480	1490	1500
*	*	*	*	*	*
CTGGGCGATC TCGCCCAGCG CAACGTGCC ACCCAAATGG GCATGTTCGC CAGGATGTTG					
GACCCGCTAG AGCGGGTCGC GTTGCACGGG TGGGTTGACC CGTACAAGCG GTCCCTACAAC					
1510	1520	1530	1540	1550	1560
*	*	*	*	*	*
CAGGCCGAGA CGCTGACCGT GGGAGAAATG GGCCGGCGTT ATGGGCCAA CGTGGGCTTC					
GTCCGGCTCT GCGACTGGCA CCCTCTTAC CCGGCCGCAA TACCGCGGTT GCACCCGAAG					
1570	1580	1590	1600	1610	1620
*	*	*	*	*	*
GTCCCGCAGT GGGCGGGAAC CCGCGAGCAG ATCGCGGACC TGATCGAGAT CCATTTCAAG					
CAGGGCGTCA CCCGCCCTG GGCGCTCGC TAGCGCCTGG ACTAGCTCTA GGTAAAGTTC					
1630	1640	1650	1660	1670	1680
*	*	*	*	*	*
GCCGGCGGGCG CCGATGGCTT CATCATCTCG CGGGCGTTCC TGCCCGGATC TTACGAGGAA					
CGGCCGCGCGC GGCTACCGAA GTAGTAGAGC GGCGCAGG ACGGGCCTAG AATGCTCCCTT					
1690	1700	1710	1720	1730	1740
*	*	*	*	*	*
TTCGTCGATC AGGTGGTGCC CATCCTGCAG CACCGCGGAC TGTTCCGCAC TGATTACGAA					
AAGCAGCTAG TCCACCAACGG GTAGGACGTC GTGGCGCCTG ACAAGGGGTG ACTAATGCTT					
1750	1760	1770	1780	1790	1800
*	*	*	*	*	*
GGCCGCACCC TGCGCAGCCA TCTGGGACTG CGTGAACCCG CATACTGGG AGAGTACGCA					
CGGGCGTGGG ACGCGTCGGT AGACCCTGAC GCACCTGGC GTATGGACCC TCTCATGCGT					

FIGURE 6C

Sphingomonas dsz sequence (page 4)

1810	1820	1830	1840	1850	1860
*	*	*	*	*	*
TGACGACAGA CATCCACCCG GCGAGCCCG CATCGTCGCC GGCGGCGC GCGACGATCA					
ACTGCTGTCT GTAGGTGGC CGCTCGCCGC TAGCAGCGG CGGCCGCGC CGCTGCTAGT					
1870	1880	1890	1900	1910	1920
*	*	*	*	*	*
CCTACAGCAA CTGCCCGTG CCTAATGCC TGCTCGCCGC GCTCGGCTCA GGTATTCTGG					
GGATGTCGTT GACGGGGCAC GGATTACGGG ACGAGCGGC CGAGCCGAGT CCATAAGACC					
1930	1940	1950	1960	1970	1980
*	*	*	*	*	*
ACAGTGCCGG GATCACACTT GCCCTGCTGA CCGGAAAGCA GGGCGAGGTG CACTTCACCT					
TGTACGGCC CTAGTGTGAA CGGGACGACT GGCCCTTCGT CCCGCTCCAC GTGAAGTGG					
1990	2000	2010	2020	2030	2040
*	*	*	*	*	*
ACGACCGAGA TGAATACACC CGCTTCGGCG GCGAGATTCC GCGCCTGGTC AGCGAGGGAC					
TGCTGGCTCT ACTGATGTGG GCGAAGCCGC CGCTCTAAGG CGCGCACCAG TCGCTCCCTG					
2050	2060	2070	2080	2090	2100
*	*	*	*	*	*
TGCCTGCGCC GGGCGGGACC CGCCTGCTGG GACTGACGCC GGTGCTGGC CGCTGGGCT					
ACGCACGCCG CCCCCCCTGG GCGGACGACC CTGACTGCGG CCACGACCCG GCGACCCCGA					
2110	2120	2130	2140	2150	2160
*	*	*	*	*	*
ACTTCGTCCG GGGCGACAGC GCGATCCGCA CCCCCGGCCGA TCTTGCCGGC CGCCGCGTCG					
TGAAGCAGGC CCCGCTGTCG CGCTAGGCCTT GGGGCCGGCT AGAACGGCCG GCGGCGCAGC					
2170	2180	2190	2200	2210	2220
*	*	*	*	*	*
GAGTATCCG ATCGGCCAGG AGGATATTGA CCGGAAGGCT GGGCGACTAC CGCGAACTTG					
CTCATAGGCT AAGCCGGTCC TCCTATAACT GGCCCTCCGA CCCGCTGATG GCGCTTGAAC					
2230	2240	2250	2260	2270	2280
*	*	*	*	*	*
ATCCCTGGCG GCAGACCCCTG GTCGCGCTGG GGACATGGGA GGCGCGTGCC TTGCTGAGCA					
TAGGGACCGC CGTCTGGGAC CAGCGCGACC CCTGTACCCCT CCGCGCACGG AACGACTCGT					
2290	2300	2310	2320	2330	2340
*	*	*	*	*	*
CGCTCGAGAC GGCAGGGCTT GGCGTCGGCG ACCTCGAGCT GACCGCGCATC GAGAACCCGT					
GCGAGCTCTG CCGCCCCGAA CCGCAGCCGC TGCAAGCTCGA CTGCGCGTAG CTCTTGGGCA					
2350	2360	2370	2380	2390	2400
*	*	*	*	*	*
TCGTCGACGT GCCGACCGAA CGACTGCATG CCGCCGGCTC GCTCAAAGGA ACCGACCTGT					
AGCAGCTGCA CGGCTGGCTT GCTGACGTAC GGCGGCCGAG CGAGTTCCCT TGGCTGGACA					

FIGURE 6D

Sphingomonas dsz sequence (page 5)

2410	2420	2430	2440	2450	2460
*	*	*	*	*	*
TCCCCGACGT GACCAGCCAG CAGGCCAG TCCTTGAGGA TGAGCGCGCC GACGCCCTGT					
AGGGGCTGCA CTGGTCGGTC GTCCGGCGTC AGGAACCTCCT ACTCGCGCGG CTGCGGGACA					
2470	2480	2490	2500	2510	2520
*	*	*	*	*	*
TCGCGTGGCT TCCCTGGCGC GCCGAGCTCG AGACCCGCAT CGGTGCACGG CCGGTCTAG					
AGCGCACCGA AGGGACCCGC CGGCTCGAGC TCTGGCGTA GCCACGTGCC GGCCAGGATC					
2530	2540	2550	2560	2570	2580
*	*	*	*	*	*
ACCTCAGCGC AGACGACCGC AATGCCTATG CGAGCACCTG GACGGTGAGC GCCGAGCTGG					
TGGAGTCGCG TCTGCTGGCG TTACGGATAC GCTCGTGGAC CTGCCACTCG CGGCTCGACC					
2590	2600	2610	2620	2630	2640
*	*	*	*	*	*
TGGACCGGCA GCCCGAACTG GTGCAGCGGC TCGTCGATGC CGTGGTGGAT GCAGGGCGGT					
ACCTGGCCGT CGGGCTTGAC CACGTGCCG AGCAGCTACG GCACCACCTA CGTCCCAGCCA					
2650	2660	2670	2680	2690	2700
*	*	*	*	*	*
GGGCGAGGC CAATGGCGAT GTCGTCTCCC GCCTGCACGC CGATAACCTC GGTGTCAGTC					
CCCGGCTCCG GTTACCGCTA CAGCAGAGGG CGGACGTGCC GCTATTGGAG CCACAGTCAG					
2710	2720	2730	2740	2750	2760
*	*	*	*	*	*
CCGAAAGCGT CCGCCAGGGG TTCGGAGCCG ATTTTCACCG CCGCCTGACG CCGCGGCTCG					
GGCTTTCGCA GGCGGTCCCT AAGCTCGGC TAAAAGTGGC GGCGGACTGC GGCGCCGAGC					
2770	2780	2790	2800	2810	2820
*	*	*	*	*	*
ACAGCGATGC TATGCCCATC CTGGAGCGTA CTCAGCGGTT CCTGAAGGAT GCGAACCTGA					
TGTCGCTACG ATAGCGGTAG GACCTCGCAT GAGTCGCCAA GGACTTCCTA CGCTTGGACT					
2830	2840	2850	2860	2870	2880
*	*	*	*	*	*
TCGATCGGTC GTTGGCGCTC GATCGGTGGG CTGCACCTGA ATTCCCTCGAA CAAAGTCTCT					
AGCTAGCCAG CAACCGCGAG CTAGCCACCC GACGTGGACT TAAGGAGCTT GTTTCAGAGA					
2890	2900	2910	2920	2930	2940
*	*	*	*	*	*
CACGCCAGGT CGAAGGGCAG ATAGCATGAA CGAACTCGTC AAAGATCTCG GCCTCAATCG					
GTGCGGTCCA GCTTCCCGTC TATCGTACTT GCTTGAGCAG TTTCTAGAGC CGGAGTTAGC					
2950	2960	2970	2980	2990	3000
*	*	*	*	*	*
ATCCGATCCG ATCGGCGCTG TGCAGCGACT GGCGCGCAG TGGGGGCCA CCGCTGTTGA					
TAGGCTAGGC TAGCCGCGAC ACGCCGCTGA CGGGCGCGTC ACCCCCCGGT GGCGACAACT					

FIGURE 6E

Sphingomonas dsz sequence (page 6)

3010	3020	3030	3040	3050	3060
*	*	*	*	*	*
TCGGGACCGG GCCGGCGGAT CGGCAACCGC CGAACTCGAT CAACTGCGCG GCAGCGGCCT					
AGCCCTGGCC CGGCCGCCTA GCGTTGGCG GCTTGAGCTA GTTGACGCC CGTCGCCGGA					
3070	3080	3090	3100	3110	3120
*	*	*	*	*	*
GCTCTCGCTG TCCATTCCCC CGGCATATGG CGGCTGGGGC GCCGACTGGC CAACGACTCT					
CGAGAGCGAC AGGTAAAGGGC GGCGTATAACC GCCGACCCCG CGGCTGACCG GTTGCTGAGA					
3130	3140	3150	3160	3170	3180
*	*	*	*	*	*
GGAAGTTATC CGCGAACGTCG CAACGGTGGA CGGATCGCTG GCGCATCTAT TCGGCTACCA					
CCTTCAATAG GCGCTTCAGC GTGCCACCT GCCTAGCGAC CGCGTAGATA AGCCGATGGT					
3190	3200	3210	3220	3230	3240
*	*	*	*	*	*
CCTCGGCTGC GTACCGATGA TCGAGCTGTT CGGCTCGCG CCACAAAAGG AACGGCTGTA					
GGAGCCGACG CATGGCTACT AGCTCGACAA GCCGAGCCGC GGTGTTTCC TTGCCGACAT					
3250	3260	3270	3280	3290	3300
*	*	*	*	*	*
CCGCCAGATC GCAAGCCATG ATTGGCGGGT CGGGAATGCG TCGAGCGAAA ACAACAGCCA					
GGCGGTCTAG CGTCGGTAC TAACCGCCCA GCCCTTACGC AGCTCGCTT TGTTGTCGGT					
3310	3320	3330	3340	3350	3360
*	*	*	*	*	*
CGTGCTCGAG TGGAAAGCTTG CCGCCACCGC CGTCGATGAT GGCGGGTTCG TCCTCAACGG					
GCACGAGCTC ACCTTCGAAC GGCGGTGGCG GCAGCTACTA CCGCCCAAGC AGGAGTTGCC					
3370	3380	3390	3400	3410	3420
*	*	*	*	*	*
CGCGAACGAC TTCTGCAGCG GCGCCAAAAG CTCCGACCTG CTCATCGTGT TCGGCGTGAT					
GCGCTTCGTG AAGACGTCGC CGCGGTTTTC GAGGCTGGAC GAGTAGCACA AGCCGCACTA					
3430	3440	3450	3460	3470	3480
*	*	*	*	*	*
CCAGGACGAA TCCCCCTGC CGGGCGCGAT CATCACCGCG GTCATTCCA CCGACCGGGC					
GGTCCTGCTT AGGGGGGACG CGCCGCGCTA GTAGTGGCGC CAGTAAGGGT GGCTGGCCCG					
3490	3500	3510	3520	3530	3540
*	*	*	*	*	*
CGGTGTTCA G ATCAATGACG ACTGGCGCGC AATCGGGATG CGCCAGACCG ACAGCGGCAG					
GCCACAAGTC TAGTTACTGC TGACCGCGCG TTAGCCCTAC GCGGTCTGGC TGTGCGCGTC					
3550	3560	3570	3580	3590	3600
*	*	*	*	*	*
CGCCGAATTG CGCGACGTCC GAGTCTACCC AGACGAGATC TTGGGGCAC CAAACTCAGT					
GCGGCTAAA GCGCTGCAGG CTCAGATGGG TCTGCTCTAG AACCCCCGTG GTTGAGTCA					

FIGURE 6F

Sphingomonas dsz sequence (page 7)

3610	3620	3630	3640	3650	3660
*	*	*	*	*	*
CGTTGAGGCG TTCGTGACAA GCAACCGCGG CAGCCTGTGG ACGCCGGCGA TTCAAGTCGAT					
GCAACTCCGC AAGCACTGTT CGTTGGCGCC GTCGGACACC TGCGGCCGCT AAGTCAGCTA					
3670	3680	3690	3700	3710	3720
*	*	*	*	*	*
CTTCTCGAAC GTTTATCTGG GGCTCGCGCG TGGCGCGCTC GAGGCCGAG CGGATTACAC					
GAAGAGCTTG CAAATAGACC CCGAGCGCGC ACCCGCGAG CTCCGCCGTC GCCTAATGTG					
3730	3740	3750	3760	3770	3780
*	*	*	*	*	*
CCGGACCCAG AGCCGCCCT GGACACCCGC CGGCGTGGCG AAGGCAGACAG AGGATCCCCA					
GGCCTGGGTC TCGGCGGGGA CCTGTGGCG GCGCACCGC TTCCGCTGTC TCCTAGGGGT					
3790	3800	3810	3820	3830	3840
*	*	*	*	*	*
CATCATCGCC ACCTACGGTG AACTGGCGAT CGCGCTCCAG GGCGCCGAGG CGGCCGCGCG					
GTAGTAGCGG TGGATGCCAC TTGACCGCTA GCGCGAGGTC CGCGGGCTCC GCCGGCGCGC					
3850	3860	3870	3880	3890	3900
*	*	*	*	*	*
CGAGGTCGCG GCCCTGTTGC AACAGGGTG GGACAAGGGC GATGCGGTGA CGCCCGAAGA					
GCTCCAGCGC CGGGACAACG TTGTCCGCAC CCTGTTCCCG CTACGCCACT GCGGGCTTCT					
3910	3920	3930	3940	3950	3960
*	*	*	*	*	*
GCGCGGCCAG CTGATGGTGA AGGTTTCGGG TGTGAAGGCC CTCTCGACGA AGGCCGCCCT					
CGCGCCGGTC GACTACCACT TCCAAGCCC ACACTCCGG GAGAGCTGCT TCCGGCGGGGA					
3970	3980	3990	4000	4010	4020
*	*	*	*	*	*
CGACATCACCG AGCCGTATTT TCGAGACAAAC GGGCTCGCGA TCGACGCATC CCAGATAACGG					
GCTGTAGTGG TCGGCATAAA AGCTCTGTTG CCCGAGCGCT AGCTGGTAG GGTCTATGCC					
4030	4040	4050	4060	4070	4080
*	*	*	*	*	*
ATTCGATCGG TTCTGGCGTA ACATCCGGAC TCATACGCTG CACGATCCGG TATCGTATAA					
TAAGCTAGCC AAGACCGCAT TGTAGGCCTG AGTATGCGAC GTGCTAGGCC ATAGCATATT					
4090	4100	4110	4120	4130	4140
*	*	*	*	*	*
AATCGTCGAT GTGGGAACT ACACGCTCAA CGGGACATTC CCGGTTCCCG GATTTACGTC					
TTAGCAGCTA CACCCCTTGA TGTGCGAGTT GCCCTGTAAG GGCCAAGGGC CTAATGCAG					

ATGA
TACT

FIGURE 6G




FIGURE 7

DszA (S)	1	MTDPROLHLAGFFCAGNVTHAHGAWRHADDSNGFLTKEYYQQIARTLERG	50
		.: : : : : . : : :	
DszA (R)	1	MTQQRQMHLAGFFSAGNVTHAHGAWRHTDASNDFLSGKYYQHIARTLERG	50
 DszA (S)	51	KFDLLFLPDALAVWDSDYGDNLETGLRYGGQGAVMLEPGVVIAAMASVTEH	100
		.: : : : . : : . :	
DszA (R)	51	KFDLLFLPDGLAVEDSYGDNLDTGVGLGGQGAVALEPASVVATMAAVTEH	100
 DszA (S)	101	LGLGATISTYYPPYHVARVVASLDQLSSGRVSWNVVTSLSNAEARNFGF	150
		: . : : : : : : : :	
DszA (R)	101	LGLGATISATYYPPYHVARVFATLDQLSGGRVSWNVVTSLNDAEARNFGI	150
 DszA (S)	151	DEHLDHDARYDRADEFLEVVRKLWNSWRDALTLDKATGQFADPAKVRYI	200
		: : : : : : : : : : : : :	
DszA (R)	151	NQHLEHDARYDRADEFLEAVKKLWNSWDEDALVLDKAAGVFADPAKVHYV	200
 DszA (S)	201	DHRGEWLNRGPLQVPRSPQGEPVILQAGLSARGKRFAGRWADAVFTISP	250
		: : : : : : : : : :..	
DszA (R)	201	DHHGEWLNRGPLQVPRSPQGEPVILQAGLSPRGRRFAGKWAEEAVFSLAP	250
 DszA (S)	251	NLDIMQATYRDIKAQVEAAGRDPHQVKVFAAVMPILGETEATARQRLEYI	300
		: : : : : : : : : : : : : :	
DszA (R)	251	NLEVMQATYQGIKAEVDAAGRDPDQTAKIFTAVMPVLGESQAVAQERLEYL	300
 DszA (S)	301	NSLVHPEVGLSTLSSHVGVNLDYSLDPLTEVLGDLAQRNVPTQLGMFA	350
		: : : : : : : : : : : :	
DszA (R)	301	NSLVHPEVGLSTLSSHTGINLAAYPLDTPIKDILRDLQDRNVPTQLHMFA	350
 DszA (S)	351	RMLQAETLTVGEMGRRYGANVGFPQWAGTREQIAIDLIEIHFKAGGADGF	400
		: : : : : : : : : : : : : :	
DszA (R)	351	AATHSEELTLAEMGRRYGTNVGFVPQWAGTGEQIADELIRHFEGGAADGF	400
 DszA (S)	401	IISPAFLPGSYEEFVDQVVPILQHTRGLFRDYEGRTLRSHLGLREPAYLG	450
		: : : : : : : : : : : : : :	
DszA (R)	401	IISPAFLPGSYDEFVDQVVPVLQDRGYFRTEYQGNTLRDHILGLRVPQLQG	450
 DszA (S)	451	EYA 453	
		:	
DszA (R)	451	QPS 453	

FIGURE 8

DszB (S)	MTTDIHPASAASSPAA--RATITYSNCPVPNALLAALGSGILDASAGITLALL	50
DszB	MTSRVDPANPGSELDSEAIRDTLTYSNCVPNALLTASESGFLDAAGIELDVL	52
DszB (S)	TGKQGEVHFTYDRDDYTRFGGEIPPLVSEGLRAPGRTRLLGLTPVLGRWGYF	102
DszB	SGQQGTVHFTYDQPAYTRFGGEIPPLLSEGLRAPGRTRLLGITPLLGROQFF	104
DszB (S)	VRGDSAIRTPADLAGRRGVSDSARRILTGRIGDYRELDPWWRQTLVALGTWE	154
DszB	VRDDSPITAAADLAGRRIGVSASAIRILRGQLGDYLELDPWWRQTLVALGSWE	156
DszB (S)	ARALLSTLETAGLVGVGDVELTRIENPFVDVPTERLHAAGSLKGTDLFPDVTS	206
DszB	ARALLHTLEHGELGVDDVELVPISSPGVDVPAEQLEESATVKGADLFPDVAR	208
DszB (S)	<u>OOAAVLEDERA DALFAWL PWAAELET RIGARPVLDLSADDRNAYASTWTVSA</u>	258
DszB	GQAAVLASGDVDALYSWLPWAGELQA-TGARPVVDLGLDERNAYASVWTVSS	260
DszB (S)	ELVDRQPELVQRLVDAVV DAGRWA EANGDV VSRL HADNLGVSPES VRQGFGA	310
DszB	GLVRQRPG LVQRLV DAAVDAGLWARDHS DA VTS LHAAN LGVSTGA VGQGFGA	312
DszB (S)	DFHRRLT PRLDSAIA ILERT QRFKLKDANL IDRSLA LDRWA APEF LEQ SLSR QVEGQIA	369
DszB	DFQQLRVPRLDHD ALA LLER TQQFL LTNNLL QEPVALDQWA APEF LNN SLN RHR	365

FIGURE 9

DszC(S)	1MNELVKDLGLNRSRDPIGAVRRLAAQWGATAVDRDRAGGSATAELD	45
DszC(R)	1	MTLSPEKQHVRPRDAADNDPVAVARGLAEKWRATAVERDRAGGSATAERE	50
DszC(S)	46	QLRGSGLLSLSIPAAYGGWGADWPTTLEVIREVATVDGSLAHLFGYHLGC	95
DszC(R)	51	DLRASALLSLLVPREYGGWGADWPTAIEVVREIAADGSLGHLFYHLTN	100
DszC(S)	96	VPMIELFGSAPQKERLYRQIASHDWGVGNASSENNSHVLEWKLAATAVDD	145
DszC(R)	101	APMIELIGSQEQEEHYTQIAQNWWTGNAASSENNSHVLDWKVSATPTED	150
DszC(S)	146	GGFVLNGAKHFCSGAKSSDLLIVFGVIQDESPLRGAIITAVIPTDRAGVQ	195
DszC(R)	151	GGYVLNGTKHFCSGAKGSDLLFVFGVQDDSPQQGAIIAAAIPTSRAVGT	200
DszC(S)	196	INDDWRAIGMRQTDSGSAEFRDVRVYPDEILGAPNSVVEAFVTSNRGSLW	245
DszC(R)	201	PNDDWAAIGMRQTDSGSTDHNVKVEPDEVLGAPNAFLAFIQSERGSLF	250
DszC(S)	246	TPAIQSIFSNVYLGLARGALEAAAADYTRTQSRPWT PAGVAKATEDPHIIA	295
DszC(R)	251	APIAQLIFANVYLGIAHGALDAAREYTRTQARPWT PAGIQQATEDPYTIR	300
DszC(S)	296	TYGELAIALQGAEEAAREVAALLQQAWDKGDAVTPEERGQLMVKVSGVKA	345
DszC(R)	301	SYGEFTIALQGADAAAREAHHLLQTWWDKGDALTPEDRGELMVKVSGVKA	350
DszC(S)	346	LSTKAALDITSRIFETTGSRSTHPRYGFDRFWRNIRTHTLHDPPSYKIVD	395
DszC(R)	351	LATNAALNISSGVFEVIGARGTHPRYGFDRFWRNVRTHSLHDPPSYKIAD	400
DszC(S)	396	VGNYTLNGTFPVPGFTS	412
DszC(R)	401	VGKHTLNGQYPIPGFTS	417

FIGURE 10




FIGURE 11

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Declaration for Patent Application

As a named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name;

I believe I am the original, first and sole inventor (if only one name is listed) or an original, first and joint inventor (if plural names are listed in the signatory page(s) commencing at page 3 hereof) of the subject matter which is claimed and for which a patent is sought on the invention entitled

A SPHINGOMONAS BIODESULFURIZATION CATALYST

the specification of which (check one)

is attached hereto.

was filed on _____ as United States Application Number or PCT International Application Serial No. _____
and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority
Not
Claim

(Number)	(Country)	(Day/Month/Year filed)	[]
(Number)	(Country)	(Day/Month/Year filed)	[]
(Number)	(Country)	(Day/Month/Year filed)	[]

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

(Application Number)	(Filing Date)
(Application Number)	(Filing Date)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information known by me to be material to patentability as defined in 37 C.F.R. §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Attorney

Docket No. EBC97-06 04/07/97 pending
(Application Serial No.) (Filing date) (Status, patented, pending, abandoned)

(Application Serial No.) (Filing date) (Status, patented, pending, abandoned)

(Application Serial No.) (Filing date) (Status, patented, pending, abandoned)

(Application Serial No.) (Filing date) (Status, patented, pending, abandoned)

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

I also hereby grant additional Powers of Attorney to the following attorney(s) and/or agent(s) to file and prosecute an international application under the Patent Cooperation Treaty based upon the above-identified application, including a power to meet all designated office requirements for designated states:

David E. Brook	Reg. No. 22,592	Thomas O. Hoover	Reg. No. 32,470
James M. Smith	Reg. No. 28,043	Alice O. Carroll	Reg. No. 33,542
Leo R. Reynolds	Reg. No. 20,884	N. Scott Pierce	Reg. No. 34,900
Patricia Granahan	Reg. No. 32,227	Richard A. Wise	Reg. No. 18,041
Mary Lou Wakimura	Reg. No. 31,804	Carolyn S. Elmore	Reg. No. 37,567

all of Hamilton, Brook, Smith and Reynolds, P.C., Two Militia Drive,
Lexington, Massachusetts 02173;

and _____

Send correspondence to: Ms. Carolyn S. Elmore
Hamilton, Brook, Smith and Reynolds, P.C.
Two Militia Drive
Lexington, Massachusetts 02173
Direct telephone calls to: Ms. Carolyn S. Elmore

(617) 861-6240

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole

or first inventor Aldis Darzins

Inventor's

Signature _____

Date _____

Residence 23 Firethorn Place

The Woodlands, TX 77381

Citizenship U.S.A.

Post Office Address Same As Above

Full name of second joint

inventor, if any Gregory T. Mrachko

Inventor's

Signature _____

Date _____

Residence 26001 Budde Road, Apt. 3802

Spring, TX 77380

Citizenship U.S.A.

Post Office Address Same As Above
